


Bi(OTf)₃-Catalyzed Multicomponent α -Amidoalkylation Reactions

Angelika E. Schneider and Georg Manolikakes*

Department of Organic Chemistry and Chemical Biology, Goethe University Frankfurt, Frankfurt am Main D-60438, Germany

S Supporting Information

ABSTRACT: A bismuth(III) triflate catalyzed three-component synthesis of α -substituted amides starting from amides, aldehydes, and (hetero)arenes is reported. The reaction has a broad substrate scope, encompassing formaldehyde as well as aryl and alkyl aldehydes. Low catalyst loadings are required, and water is formed as the only side product. The scope and limitation of this method will be discussed.



INTRODUCTION

Amino- and amidoalkyl moieties are important structural motifs in organic synthesis and pharmaceutical chemistry.^{1–3} α -Substituted amides, in particular amidoalkylated arenes and heteroarenes, are found in many important natural products and biological active molecules such as luotonin A,² an alkaloid, or the antiretroviral Raltegravir³ (Figure 1).




Figure 1. Amidoalkylated moieties in biologically active molecules.

An important approach for the synthesis of this structural motif is the addition of nucleophilic (hetero)arenes to electrophilic carbon–nitrogen double bonds. In particular, three-component aza-Friedel–Crafts-type amidoalkylations with in situ generated acylimines or acyliminium ions provide a useful synthetic tool for the synthesis of α -substituted amides.^{4,5} The in situ preparation of these reactive imine compounds from an aldehyde and an amide represents an atom-economical methodology⁶ for the synthesis of amidoalkylated (hetero)arenes. Generating water as the only side product, these reactions could meet the requirements of modern sustainable organic synthesis.⁷ However, most common procedures require stoichiometric amounts of Lewis or Brønsted acids⁸ or are limited to the reaction of electron-rich aromatics and heteroaromatics, such as indole and naphthol.^{9–12}

Our interest in developing novel multicomponent reactions for the rapid synthesis of pharmaceutically active molecules^{13–15} has led us to a closer examination of these three-component reactions. In the course of our investigations, we were able to develop a Bi(OTf)₃-catalyzed three-component reaction between amides, formaldehyde, and arenes. This reaction provides straightforward access to amidomethylated arenes and heteroarenes.¹³ Recently, the group of Jaratjaroonphong reported a similar Bi(OTf)₃-catalyzed three-component reaction between

carbamates, aldehydes, and arenes.¹⁶ However, this reaction is limited to very electron-rich trimethoxybenzene derivatives or reactive heteroarenes such as furan, thiophene, or indole.¹⁷ Herein, we report the extension of our method to aryl and alkyl aldehydes as well as the scope and limitations of the corresponding reactions and mechanistic investigations.

RESULTS AND DISCUSSION

1. Three-Component Reaction with Formaldehyde. We started our investigations with the identification of a suitable catalyst using the reaction between benzamide (1), paraformaldehyde (2), and *m*-xylene (3), a moderately reactive arene, as a test system (Table 1). From a multitude of tested metal triflates


Table 1. Formaldehyde: Survey of Catalysts^{a,b}

entry	catalyst (mol %)	yield (%)
1	M(OTf) _x (5.0) M = Cu, Zn, In, Sc, Mg, Yb, etc.	<5
2	BiBr ₃ (5.0)	<5
3	BiCl ₃ (5.0)	<5
4	Bi(OTf) ₃ (1.0) ^{c,d}	71
5	Bi(OTf) ₃ (2.5) ^{c,d}	85
6	Bi(OTf) ₃ (5.0) ^c	61
7	Bi(OTf) ₃ (5.0) ^{c,d}	84
8	Bi(OTf) ₃ (5.0) ^{c,d,e}	79
9	TfOH (5.0)	10
10	Bi(OTf) ₃ (5.0) + dbpy (10.0) ^{c,d}	75


^aGeneral reaction conditions: benzamide (1.0 equiv), paraformaldehyde (1.2 equiv), *m*-xylene (3.0 equiv), catalyst (*x* mol %). ^bIsolated yield of analytical pure product. ^cObtained as a 15:1 mixture of regioisomers. ^dReaction in MeNO₂. ^eReaction with aqueous formalin.

Received: March 24, 2015

Published: May 21, 2015

Scheme 1. Formaldehyde: Variation of Amides^a

^aIsolated yield of analytical pure product. ^bObtained as a mixture of regioisomers; ratio of regioisomers given in parentheses. ^cReaction at 60 °C.


Scheme 2. Reaction of Phthalyl-Protected Valinamide^a

^aIsolated yield of analytical pure product. ^bObtained as a mixture of regioisomers; ratio of regioisomers given in parentheses.

and Bi(III) salts (entries 1–3) only Bi(OTf)₃ efficiently catalyzed the transformation even at low catalyst loadings (entries 4–8, 61–85% yield). Since Bi(OTf)₃ is commercially available, nontoxic, and air- and moisture-stable, it is a very attractive catalyst.^{18–20} Performing the reaction in nitromethane led to an increased yield. Best results could be achieved with 2.5 mol % of Bi(OTf)₃ (entry 5, 85% yield). Replacement of paraformaldehyde by aqueous formalin solution as formaldehyde source furnished the product in comparable yield (entries 7 and 8). TfOH, a possible byproduct of the hydrolysis of Bi(OTf)₃, displayed reduced catalytic activity (entry 9). To exclude a possible hidden Brønsted acid catalysis, the reaction was performed in the presence of the selective proton scavenger 2,6-di-*tert*-butylpyridine (dbpy) (entry 10).²¹ Since no significant decrease in catalytic activity was observed, the Bi(III) species is assumed to be the active catalyst.²² In all cases, the amidoalkylated product was obtained as a mixture of regioisomers (15:1 *ortho/para*- vs *ortho/ortho*-substitution).

With the optimized conditions established, the scope of the reaction was examined (Scheme 1). Conversion of substituted benzamides led to the products **6a** and **6b** in 65–70% yield. With carbamates as amide component, the corresponding *N*-protected amidomethylarenes **6c** and **6d** were obtained in 45% and 71% yield, respectively. Deprotection of such products would offer a straightforward access to α -aminomethylarenes, which are found in various bioactive substances.²³ Reactions with various alkylamides furnished the corresponding amidoalkylated products in good to excellent yields. Acid-sensitive functionalities, such as an acrylamide, were well tolerated (product **6e**). With the exception of oxazolidin-2-one (product **6j**), secondary amides did not react under the standard conditions. Similar regioselectivities are observed for all different amide components.

In addition, highly functionalized amides are suitable substrates for this three-component reaction. Thus, the reaction of the protected valinamide **7** provided the amino acid derivative **8** in 63% yield (Scheme 2).²⁴

Scheme 3. Formaldehyde: Variation of (Hetero)arenes^a


^aIsolated yield of analytical pure product. ^bObtained as mixture of regioisomers; ratio of regioisomers given in parentheses. ^cReaction at 80 °C. ^d4.0 equiv of arene. ^eReaction at rt. ^fReaction with aqueous formalin. ^gReaction at 40 °C.

Next, reactions with different aromatic components were examined. Various electron-rich arenes such as mesitylene, anisole, and its halogenated derivatives furnished the desired α -amidoalkylated products in good to excellent yields (**10a–h**, 42–88% yield). In general, the α -amidomethylated arenes were obtained with high regioselectivity. Only with anisole as arene was obtained a 1:3 mixture of *ortho*- and *para*-substituted regioisomers, typical for electrophilic aromatic substitutions.²⁵ Unprotected phenols or acid-labile ester functionalities were well tolerated under the reaction conditions (products **10m** and **10j**). The reaction with sterically hindered pivaloyl amide proceeded in a chemoselective manner, and the amidoalkylated product **10k** was obtained in 66% yield. Less electron-rich arenes, such as toluene or benzene, did not react even under more forcing conditions. In the case of electron-rich heteroarenes, lower reaction temperatures were required to avoid direct addition of the heteroarene to formaldehyde. Several electron-rich heteroaromatics gave the corresponding amidomethylated products in

33–94% yield (Scheme 3, products **10o–s**). For some of these reactions considerably higher yields could be obtained with aqueous formalin as aldehyde source (**10o,q,s**). Regioselective amidoalkylation at the more reactive 2-position over the 3-position was observed for benzofuran and thiophene.


1.1. Mechanistic Considerations. For the development of the three-component reaction, the in situ generation of a reactive acylimine species as electrophilic amidoalkylating agent was assumed to be the first crucial step. Therefore, we investigated the two-component reaction between formaldehyde and benzamide, which should lead to the corresponding acylimine or acyliminium ion. However, we were not able to detect or isolate any acylimine species.²⁶ The only product we could obtain from the two-component reaction was bisamide **11**, derived from a two-fold addition of benzamide to formaldehyde. This bisamide is formed very rapidly in almost quantitative yield (Scheme 4).

Scheme 4. Formation of Bisamide



In the case of the three-component reactions, we were able to observe the same rapid formation of the bisamide and a slower subsequent conversion of the bisamide to the product during the course of the reaction. It is worth mentioning that we could observe the formation of this bisamide during our initial catalyst screenings with almost every tested Lewis or Brønsted acid.²⁷ Some Brønsted acids, e.g., TfOH, could catalyze the bisamide formation even more efficiently than Bi(OTf)₃. Treatment of the bisamide **11** with 2-bromoanisole as the nucleophilic arene component in the presence of 5 mol % of Bi(OTf)₃ furnished the expected amidoalkylated product **10d** in 67% yield (Scheme 5).

Scheme 5. Two-Component Reactions with Preformed Acylimine Precursors



The analogous N,O-aminal **12**, the formal monoaddition product of benzamide to formaldehyde, reacts in a similar manner. Treatment of **12** with bromoanisole in the presence of 5 mol % of Bi(OTf)₃ leads to the formation of the amidoalkylation product in 61% yield. No other tested Lewis or Brønsted acid

could catalyze those two transformations with comparable efficiency.


On the basis of those experiments, we assume the following mechanism as shown in Scheme 6. In the first step, the amide adds to the aldehyde to afford an aminal. Elimination of water leads to the formation of a reactive acylimine or acyliminium species.²⁸ This electrophilic species reacts immediately with a second molecule of the amide in aza-amidoalkylation to furnish the observed and isolated bisamide. Considering the higher nucleophilicity of the amide nitrogen, the fast addition of a second amide to the acylimine is not surprising. Under the reaction conditions, the bisamide, favored under kinetic control, can decompose to form the acylimine. In the presence of a suitable nucleophilic arene, the electrophilic acylimine can react in an aza-Friedel–Crafts reaction to afford the amidoalkylated product containing a thermodynamically stable C–C bond. The unique catalytic activity of Bi(OTf)₃ can be explained by two reasons. On the one hand, Bi(OTf)₃, although easily hydrolyzed,^{20b} does not lose its catalytic activity in the presence of higher amounts of water.¹⁹ On the other hand, Bi(OTf)₃ is a strong Lewis acid and could further activate the formed acylimine toward the addition of nucleophiles.²⁹

During our studies, we often observed the formation of bis(hetero)arylmethane derivatives, especially for reactions with more reactive (hetero)arenes such as thiophene, furan, or *N*-tosylindole.³⁰ Since we were never able to isolate the amidoalkylation products of very reactive heteroarenes, such as indole, we cannot rule out that these products decompose under our reaction conditions. Control experiments showed that these side products arise from the direct addition of two (hetero)arenes to the aldehyde, presumably via in situ formed benzyl cations (Scheme 7).³¹


The amidoalkylated products proved to be stable under our reaction conditions. Prolonged treatment of **4** with excess *m*-xylene in the presence of 5 mol % of Bi(OTf)₃ did not lead to the formation of any diarylmethane (Scheme 8).

2. Three-Component Reaction with Alkylaldehydes.


Encouraged by the results of the α -amidoalkylation reaction with formaldehyde, we turned our attention to reactions with simple alkylaldehydes. Unfortunately, the reaction of benzamide (**1a**),

Scheme 6. Proposed Mechanism of the Three-Component α -Amidoalkylation Reaction

Scheme 7. Side Reaction with Electron-Rich (Hetero)arenes




Scheme 8. Stability of Amidoalkylated Products



isobutyraldehyde (13), and mesitylene (9a) led to the selective formation of enamide 14 in 75% yield (Scheme 9).³²

Scheme 9. Multicomponent Reactions with Alkylaldehydes Fail at Elevated Temperatures



Therefore, the corresponding two-component reaction between benzamide and isobutyraldehyde was investigated in more detail (Scheme 10). These investigations revealed a rapid formation of the corresponding bisamide 15 in the presence of $\text{Bi}(\text{OTf})_3$ even at room temperature. However, this bisamide is not stable at elevated temperatures. At temperatures above 35 °C, formation of the enamide occurs, presumably via elimination of one molecule of benzamide.³³ Enamide 14 is stable in the presence of $\text{Bi}(\text{OTf})_3$ at temperatures below 100 °C. In the presence of stronger acids or at higher temperatures, dimerization and polymerization of the enamide are observed.

From these results, we can draw two conclusions. On the one hand, alkylaldehydes are not suitable aldehyde components for our amidoalkylation reactions with moderately nucleophilic arenes. On the other hand, the formation of bisamide 15 clearly shows that a reactive acylimine species is formed even at room temperature. Therefore, trapping of the electrophilic acylimine with more reactive, electron-rich (hetero)arenes at temperatures below 35 °C should be possible. With these considerations in mind, we investigated the three-component reaction between benzamide (1), isobutyraldehyde (13), and 2-methylfuran (16) as a more nucleophilic arene component (Table 2).¹⁷ Indeed, $\text{Bi}(\text{OTf})_3$ can efficiently catalyze this reaction at 2–5 mol % catalyst loading. The yield of the reaction can be improved by a slight modification of the reaction protocol. Slow addition of the nucleophilic component over 2 h leads to an increased yield and decreased direct addition of the arene to the aldehyde.

With the optimized conditions in hand, we investigated reactions with different alkylaldehydes. In general, the desired amidoalkylated products were obtained in moderate to high

Table 2. Alkylaldehydes: Survey of Catalysts^{a,b}

entry	catalyst (mol %)	yield (%)
1	$\text{Bi}(\text{OTf})_3$ (0.5)	
2	$\text{Bi}(\text{OTf})_3$ (1.0)	
3	$\text{Bi}(\text{OTf})_3$ (2.0)	44
4	$\text{Bi}(\text{OTf})_3$ (2.0) ^c	61
5	$\text{Bi}(\text{OTf})_3$ (5.0)	35
6	BiCl_3 (5.0)	
7	BiNO_3 (5.0)	

^aGeneral reaction conditions: benzamide (1.2 equiv), isobutyraldehyde (1.0 equiv), 2-methylfuran (3.0 equiv), $\text{Bi}(\text{OTf})_3$ (x mol %).
^bIsolated yield of analytical pure product. ^cThe arene was added dropwise over a period of 2 h to the reaction mixture.

yields (Scheme 11). In the case of 2-benzyloxyacetaldehyde, the corresponding 1,2-amino alcohol 19d could be isolated in 77% yield. Reactions of alkylaldehydes bearing a stereocenter in the α -position furnished the amides 19b and 19f in good yields and moderate to high diastereoselectivities.

Different amides and carbamates are suitable amide components for this three-component reaction. The reaction with alkyl amides or various carbamates leads to the formation of amidoalkylated furans in 32–76% yield (Scheme 12). *tert*-Butyl carbamate is a suitable substrate for this transformation (product 20e).


The acid-sensitive Boc functionality is well tolerated under the very mild reaction conditions (Scheme 13). The reaction of Boc-protected valinamide 21 furnished the corresponding product 22 in 62% yield and with a 2:1 diastereoselectivity.


As indicated above, three-component reactions with alkylaldehydes are limited to electron-rich arenes and heteroarenes. Therefore, the reaction of 2-methylthiophene and 1,3-dimethoxybenzene furnished the products 23a and 23c in 61 and 58% yield (Scheme 14). Further examination of this three-component reaction revealed a second limitation. Very reactive heteroarenes, such as indole or pyrrole, are not suitable substrates for this transformation. In the case of such highly reactive aromatic components only direct addition to the aldehyde is observed.

3. Three-Component Reaction with Aryl Aldehydes.

We next turned our attention to reactions with aryl aldehydes as the aldehyde component. In this case, enamide formation is not

Scheme 10. Two-Component Reaction between Benzamide and Isobutyraldehyde



Scheme 11. Alkylaldehydes: Variation of Aldehydes^a

^aIsolated yield of analytical pure product. ^bThe reaction mixture was cooled to 0 °C, and then the arene was added. ^cThe arene was added dropwise over a period of 1 h to the reaction mixture. ^dObtained as a mixture of diastereomers; ratio of diastereomers given in parentheses. ^eThe arene was added dropwise over a period of 2 h to the reaction mixture. Pht = *N*-phthalyl.

possible. During preliminary experiments, rapid formation of the bisamide intermediate was observed at temperatures higher than 50 °C. The reaction between benzamide (**1**), benzaldehyde (**24**), and mesitylene (**9a**) was chosen as a model system to investigate the influence of various reaction parameters (Table 3). Surprisingly, high temperatures of 130 °C were required for efficient product formation. Best yields were obtained using 10 mol % of Bi(OTf)₃ (entry 4, 71%). We attribute these forcing reaction conditions with the decreased electrophilicity of *N*-acylimines derived from aryl aldehydes. Comparable results in yields were provided either by lengthening of the reaction time to 48 h or performing the reaction at 150 °C (entries 2 and 3, 63 and 60% yield). Addition of Brønsted acids, such as TfOH, did not affect the yield (entry 5).

The use of TfOH as Brønsted acid additive in the three-component reaction with less reactive *m*-xylene led to considerably higher yield (Table 4, entries 1 and 3). Best yields of **26** were obtained by an additional increase of temperature to 150 °C (entry 4).

With the optimized reaction conditions at hand, we examined reactions with various aryl aldehydes (Scheme 15). Aryl aldehydes bearing halogens in the *meta* or *para* position afforded the products in good yields (**28a–d**, 54–72% yield). Reaction with 2-chloro-5-nitrobenzaldehyde provided the product **28e** in 66% yield. The α -amidoalkylated product **28f** of naphthylaldehyde was isolated in 29% yield.

As shown in Scheme 16, variation of the amide component afforded the desired products **29a–d**; **29f,g** in 33–89% yield. In the case of aryl aldehydes, carbamates are not suitable amide components. Only in the case of urethane was the desired product **29g** formed, albeit in only 33% yield. Most likely, carbamates are not stable under these conditions.

Next, we investigated reactions with various arenes (Scheme 17). Anisole and its halogenated derivatives gave the desired amidoalkylated products **30a–d** in 25–40% yield. Only in the case of 3,5-*di*-methylanisole was the α -substituted amide isolated in a satisfactory yield of 74%. In general, reactions with various electron-rich heterocycles were not successful. The intermediate species is efficiently generated at 50 °C, but the high reactivity of the heteroarenes promotes synthesis of the direct addition products at these temperatures. Best results were achieved with 2-bromothiophene (**30f**, 36% yield). The high reactivity of the heteroarenes leads to a rapid direct addition to the aldehyde temperatures below 50 °C, necessary for the acylimine formation.


CONCLUSIONS

In summary, a general Bi(OTf)₃-catalyzed multicomponent between amides, aldehydes and arenes was developed. Formaldehyde, alkylaldehydes and aryl aldehydes were successfully employed as aldehyde compounds. Scope and limitations for all three types of aldehyde components were investigated.


These practical and operational simple multicomponent reactions provide straightforward and versatile access to α -amidoalkylated (hetero)arenes. The use of the nontoxic catalyst and generation of water as only side product constitute a valuable approach toward the concept of sustainable chemistry.

EXPERIMENTAL SECTION

General Considerations. Solvents for reactions and column chromatography were obtained from different commercial suppliers in >97% purity and used as received. Reagents: (*S*)-*N*-(2,4-Dimethylbenzyl)-3-methyl-2-(1,3-dioxisoindolin-2-yl)butanamide,³⁴ *N*-benzyl-2-oxoacetamide,³⁵ ethyl-4-methoxybenzoate,³⁶ 3,5-dimethylanisole,³⁷ 2-

Scheme 12. Alkylaldehydes: Variation of Amides^a

^aIsolated yield of analytical pure product. ^bThe arene was added dropwise over a period of 2 h to the reaction mixture. ^cThe bis(heteroaryl)phenylpropane species was formed as the major product. ^dThe reaction mixture was cooled to 0 °C, and then the arene was added. ^eThe arene was added dropwise over a period of 1 h to the reaction mixture.

Scheme 13. Alkylaldehydes: Reaction of Boc-Protected Valinamide^{a–c}


^aIsolated yield of analytical pure product. ^bThe arene was added dropwise over a period of 2 h to the reaction mixture. ^cObtained as a mixture of diastereomers; ratio of diastereomers given in parentheses.

methylpivalanilide,³⁸ 3-ethylpivalanilide,³⁸ *N*-tosylindole,³⁹ and *N*-tosylpyrrole⁴⁰ were synthesized according to the literature. All other starting materials were purchased from commercial sources and used without further purification. Anhydrous Bi(OTf)₃ was obtained from different providers and used directly. No special precautions were taken to avoid exposure of Bi(OTf)₃ to moisture. Therefore, we cannot rule out the formation of Bi(OTf)₃·*x*H₂O during storage. Indeed, depending on the provider and storage time (or even the time for weighting out a defined amount for elemental analysis), Bi(OTf)₃ contained up to six molecules of water. However, no changes in catalytic activity and yield even upon prolonged storage (>1 year) were observed. Therefore, the amount of Bi(OTf)₃ used is always calculated on anhydrous Bi(OTf)₃. The actual catalyst loading for particular reactions might be slightly lower, depending on the batch quality and storage time. Column chromatography was performed with silica 0.04–0.063 mm/230–400 mesh. Thin-layer chromatography was done using aluminum plates coated with SiO₂. The spots were visualized by ultraviolet light, iodine, or CAM. NMR spectroscopy: ¹H and ¹³C NMR spectra were recorded

at 300 or 400 MHz and 75 or 101 MHz, respectively. Mass spectra (MS) were measured using ESI (electrospray ionization) coupled to a quadrupole mass mass analyzer. High-resolution mass spectra (MALDI-HRMS) were measured using MALDI (matrix-assisted laser desorption/ionization) coupled to an ion-trap mass spectrometer. Melting points are uncorrected. All yields refer to isolated yields of compounds estimated to be >95% pure as determined by ¹H NMR or elementary analysis.

Typical Procedures. All reactions were performed in vials sealed with a screw cap to avoid evaporation of the solvent. For reactions performed at room temperature, the screw cap was replaced with a rubber septum. For reactions performed at temperatures below the boiling point of the solvent culture, tubes with a PTFE-lined screw cap were used. For reactions performed at or above the boiling point of the solvent special thick-walled pressure tubes have to be used.

TP 1: Reactions with Formaldehyde. A 10 mL screw cap vial was charged with Bi(OTf)₃ (5 mol %), amide (1.0 equiv), formaldehyde (1.2 equiv), (hetero)arene (3–4 equiv), and nitromethane and closed with a

Scheme 14. Alkylaldehydes: Variation of (Hetero)arenes^a

^aIsolated yield of analytical pure product. ^bReaction at 35 °C. ^c5 mol % of Bi(OTf)₃. ^dThe bis(heteroaryl)phenylpropane species was formed. ^eThe reaction mixture was cooled to 0 °C, and then the arene was added.

Table 3. Aryl aldehydes: Optimization of Catalysts^{a,b}

entry	catalyst (mol %)	yield (%)
1	Bi(OTf) ₃ (5.0)	23
2	Bi(OTf) ₃ (5.0) ^c	63
3	Bi(OTf) ₃ (5.0) ^d	60
4	Bi(OTf) ₃ (10.0)	71
5	Bi(OTf) ₃ (5.0) + TfOH (5.0)	25

^aGeneral reaction conditions: benzamide (1.0 equiv), benzaldehyde (1.2 equiv), mesitylene (3.0 equiv), Bi(OTf)₃ (x mol %), 130 °C, 24 h.

^bIsolated yield of analytical pure product. ^cReaction time: 48 h. ^dReaction at 150 °C.

Table 4. Aryl aldehydes: Use of TfOH Elevates Yield in the Case of *m*-Xylene^{a,b}

entry	catalyst (mol %)	yield (%)
1	Bi(OTf) ₃ (5.0) ^c	43
2	Bi(OTf) ₃ (10.0)	35
3	Bi(OTf) ₃ (5.0) + TfOH (5.0) ^{d,e}	58
4	Bi(OTf) ₃ (5.0) + TfOH (5.0) ^{e,f}	76

^aGeneral reaction conditions: benzamide (1.0 equiv), benzaldehyde (1.2 equiv), mesitylene (3.0 equiv), Bi(OTf)₃ (x mol %), 130 °C, 24 h.

^bIsolated yield of analytical pure product. ^cReaction time: 48 h. ^dReaction at 100 °C. ^eBenzamide (1.2 equiv), benzaldehyde (1.0 equiv). ^fReaction at 150 °C.

Teflon lined screw cap. The reaction mixture was stirred at 25–100 °C for the specified time. After being cooled to room temperature, the


reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by column chromatography (hexane/EtOAc) afforded the analytically pure product.

TP 2: Reactions with Aryl aldehydes. A 10 mL screw cap vial was charged with Bi(OTf)₃ (10 mol %), amide (1.0 equiv), aryl aldehyde (1.2 equiv), (hetero)arene (3–4 equiv), and nitromethane and closed with a Teflon lined screw cap. The reaction mixture was stirred at 50–130 °C for the specified time. After being cooled to room temperature, the reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by column chromatography (hexane/EtOAc) afforded the analytically pure product.


***N*-(2,4-Dimethylbenzyl)benzamide (4).** Compound 4 was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *m*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 5 mol %) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (403 mg, 84%, ratio of regioisomers 15:1). Mp: 94–95 °C. ¹H NMR (CDCl₃, 400 MHz) (peaks are listed only for major regioisomer): δ = 7.77 (d, *J* = 8 Hz, 2H), 7.51–7.47 (m, 1H), 7.44–7.40 (m, 2H), 7.19 (d, *J* = 8 Hz, 1H), 7.04–7.00 (m, 2H), 6.17 (bs, 1H), 4.61 (d, *J* = 5 Hz, 2H), 2.34 (s, 3H), 2.32 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz) (peaks are listed only for major regioisomer): δ = 167.3, 137.8, 136.7, 134.6, 132.9, 131.6, 129.1, 128.7, 128.7, 127.0, 127.0, 42.3, 21.1, 19.1. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₁₈NO 240.14, found 240.40. Anal. Calcd: C, 80.30; H, 7.16; N, 5.85. Found: C, 80.13; H, 7.06; N, 5.78. IR (cm⁻¹): 3284 (m), 1626 (s), 1578 (m), 1524 (m), 1487 (w), 1474 (w), 1363 (w), 1308 (m), 1281 (m), 1219 (w), 1182 (w), 1144 (w), 1057 (w), 1055 (w), 1026 (w), 968 (w), 920 (w), 877 (w), 831 (w), 823 (m), 800 (m), 769 (m), 704 (w), 690 (s), 660 (w). *R*_f (hexane/EtOAc 4:1) = 0.3.

***N*-(2,4-Dimethylbenzyl)-4-methoxybenzamide (6a).** Compound 6a was synthesized according to TP 1 from 4-methoxybenzamide (76 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), *m*-xylene (0.24 mL, 2.0 mmol, 4 equiv), and Bi(OTf)₃ (16 mg, 0.025 mmol) in nitromethane (2 mL) at 80 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (87 mg, 65%). Mp: 134–135 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.73 (d, *J* = 8.3 Hz, 2H), 7.19 (d, *J* = 7.6 Hz, 1H), 7.03–6.99 (m, 2H), 6.90 (d, *J* = 8.4 Hz, 2H), 6.07 (bs, 1H), 4.58 (d, *J* = 5.1 Hz, 2H), 3.84 (s, 3H), 2.33 (s, 3H), 2.32 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 166.8, 162.3, 137.8, 136.7, 133.1, 131.6, 129.1, 128.9, 127.0, 126.8, 113.9, 55.5, 42.3, 21.1, 19.1. MS (ESI) *m/z*: calcd for C₁₇H₁₉NO₂Na 292.13; found 292.21 [M + Na]⁺. Anal. Calcd: C, 75.81; H, 7.11; N, 5.20. Found: C, 75.61; H, 6.91; N, 5.10. IR (cm⁻¹): 3284 (m), 1618 (s), 1574 (w), 1531 (m), 1497 (m), 1462 (m), 1408 (w), 1367 (w), 1304 (m), 1281 (m), 1250 (s), 1176 (m), 1111 (w), 1032 (m), 968 (w), 533 (w), 883 (w), 843 (m), 823 (s), 771 (m), 683 (w). *R*_f (hexane/EtOAc 4:1) = 0.1.

***N*-(2,4-Dimethylbenzyl)-4-bromobenzamide (6b).** Compound 6b was synthesized according to TP 1 from 4-bromobenzamide (400 g, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *m*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (448 mg, 70%, ratio of regioisomers 24:1). Mp: 174–175 °C. ¹H NMR (CDCl₃, 400 MHz) (peaks are listed only for major regioisomer): δ = 7.63 (d, *J* = 7.6 Hz, 2H), 7.55 (d, *J* = 7.5 Hz, 2H), 7.17 (d, *J* = 7.6 Hz, 1H), 7.04–7.00 (m, 2H), 6.12 (bs, 1H), 4.59 (d, *J* = 5.1 Hz, 2H), 2.33 (s, 3H), 2.32 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 166.3, 138.0, 136.7, 133.4, 132.6, 132.0, 131.7, 129.2, 128.7, 127.1, 126.3, 42.4, 21.2, 19.1. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₁₇BrNO 318.04, found 318.00. Anal. Calcd: C, 60.39; H, 5.07; N, 4.40. Found: C, 60.23; H, 5.02; N, 4.21. IR (cm⁻¹): 3286 (w), 2906 (w), 1626 (s), 1589 (w), 1529 (m), 1481 (m), 1358 (w), 1304 (w), 1277 (w), 1180 (w), 1146 (w), 1072 (w), 1009 (m), 972 (w), 881 (w), 843 (m), 823 (m), 771 (w), 756 (w), 677 (w). *R*_f (hexane/EtOAc 4:1) = 0.4.

Scheme 15. Aryl aldehydes: Variation of Aldehydes^a


^aIsolated yield of analytical pure product. Mes = mesityl (2,4,6-trimethylphenyl).

Scheme 16. Aryl aldehydes: Variation of Amides^a

^aIsolated yield of analytical pure product. ^bReaction at 100 °C. Mes = mesityl (2,4,6-trimethylphenyl).

Ethyl 2,4-Dimethylbenzylcarbamate (6c). Compound **6c** was synthesized according to TP 1 from urethane (45 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), *m*-xylene (0.18 mL, 1.5 mmol, 3.0 equiv), and Bi(OTf)₃ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2

mL) at 60 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (73 mg, 71%). Mp: 54–55 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.13 (d, *J* = 7.4 Hz, 1H), 6.99–6.97 (m, 2H), 4.76 (bs, 1H), 4.32 (d, *J* = 5.2 Hz, 2H), 4.14 (q, *J* = 6.9, 6.9

Scheme 17. Aryl aldehydes: Variation of (Hetero)arenes^a

^aIsolated yield of analytical pure product. ^bObtained as a mixture of regioisomers; ratio of regioisomers given in parentheses. ^cReaction at 100 °C. ^dReaction with 5 mol % of $\text{Bi}(\text{OTf})_3$. ^eReaction with 5 mol % of TFOH. ^fReaction at 80 °C. ^gReaction at 50 °C.

Hz, 2H), 2.31 (s, 6H), 1.25 (t, $J = 7.0$ Hz, 3H). ¹³C NMR (CDCl_3 , 101 MHz): $\delta = 156.6, 137.5, 136.2, 133.3, 131.5, 128.5, 126.9, 61.0, 43.0, 21.1, 19.0, 14.8$. MS (ESI) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{12}\text{H}_{17}\text{NO}_2\text{Na}$ 230.12, found 230.23. HRMS (MALDI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{18}\text{NO}_2$ 208.1332, found 208.1333. IR (cm^{-1}): 3321 (m), 2979 (m), 2921 (w), 1686 (s), 1617 (w), 1525 (m), 1479 (m), 1470 (m), 1375 (m), 1356 (m), 1301 (m), 1243 (s), 1160 (m), 1128 (m), 1047 (s), 965 (m), 925 (m), 880 (m), 822 (s), 780 (m), 638 (m), 638 (m), 580 (s), 550 (m), 505 (m). R_f (hexane/EtOAc 4:1) = 0.4.

Benzyl 2,4-Dimethylbenzylcarbamate (6d). Compound **6d** was synthesized according to TP 1 from benzylcarbamate (76 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), *m*-xylene (0.18 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2 mL) at 60 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (61 mg, 45%, ratio of regioisomers 14:1). Mp: 74–76 °C. ¹H NMR (CDCl_3 , 400 MHz) (peaks are listed only for major regioisomer): $\delta = 7.36\text{--}7.30$ (m, 5H), 7.12 (d, $J = 7.5$ Hz, 1H), 6.99–6.97 (m, 2H), 5.13 (s, 2H), 4.85 (bs, 1H), 4.35 (d, $J = 5.5$ Hz, 2H), 2.30 (s, 3H), 2.29 (s, 3H). ¹³C NMR (CDCl_3 , 101 MHz) (compound exists as a mixture of rota- and regioisomers, peaks are not assigned): $\delta = 156.3, 137.5, 136.7, 136.2, 133.1, 131.5, 128.7, 128.5, 128.3, 128.0, 126.9, 126.8, 66.9, 43.2, 21.1, 19.0$. MS (ESI) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_2\text{Na}$ 292.13, found 292.21. Anal. Calcd: C, 75.81; H, 7.11; N, 5.20. Found: C, 75.67; H, 7.09; N, 4.97. IR (cm^{-1}): 3318 (w), 2946 (w), 2921 (w), 1683 (s), 1519 (s), 1505 (s), 1463 (m), 1453 (m), 1379 (w), 1356 (m), 1303 (w), 1241 (s), 1159 (w), 1118 (m), 1080 (w), 1047 (s), 1028 (m), 1003 (w), 965 (m), 925 (w), 912 (m), 881 (w), 852 (m), 823 (m), 780 (m), 756 (s), 719 (m), 706 (m), 693 (m), 627 (m), 588 (s), 568 (m), 538 (m), 504 (m), 468 (m). R_f (hexane/EtOAc 4:1) = 0.5.

***N*-(2,4-Dimethylbenzyl)-2-acrylamide (6e)**. Compound **6e** was synthesized according to TP 1 from acrylamide (142 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *m*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (207 mg, 55%, ratio of regioisomers 13:1). Mp: 122–123 °C. ¹H NMR (CDCl_3 , 400 MHz) (peaks are listed only for major regioisomer): $\delta = 7.14\text{--}7.12$ (m, 1H), 7.01–6.68 (m, 2H), 6.31 (dd, $J = 17.0, 1.5$ Hz, 1H), 6.12–6.08 (m, 1H),

5.65 (dd, $J = 10.2, 1.5$ Hz, 1H), 4.48 (d, $J = 5.4$ Hz, 2H), 2.31 (s, 3H), 2.30 (s, 3H). ¹³C NMR (CDCl_3 , 101 MHz) (peaks are listed only for major regioisomer): $\delta = 165.3, 137.8, 136.6, 132.7, 131.6, 130.8, 129.1, 127.0, 126.7, 41.8, 38.5, 21.1, 19.0$. MS (ESI) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{12}\text{H}_{15}\text{NONa}$ 212.11, found 212.17. Anal. Calcd: C, 76.16; H, 7.99; N, 7.40. Found: C, 76.02; H, 7.79; N, 7.32. IR (cm^{-1}): 3286 (m), 2916 (w), 1653 (s), 1620 (s), 1537 (m), 1464 (w), 1404 (w), 1352 (w), 1304 (w), 1234 (s), 1046 (m), 995 (s), 145 (s), 879 (w), 822 (m), 775 (w), 688 (m). R_f (hexane/EtOAc 4:1) = 0.1.

***N*-(2,4-Dimethylbenzyl)-2-chloroacetamide (6f)**. Compound **6f** was synthesized according to TP 1 from 2-chloroacetamide (187 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *m*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (308 mg, 73%, ratio of regioisomers 18:1). Mp: 120–121 °C. ¹H NMR (CDCl_3 , 300 MHz) (peaks are listed only for major regioisomer): $\delta = 7.13$ (d, $J = 7.5$ Hz, 1H), 7.02–7.00 (m, 2H), 6.63 (bs, 1H), 4.45 (d, $J = 5.4$ Hz, 2H), 4.09 (s, 2H), 2.32 (s, 3H), 2.30 (s, 3H). ¹³C NMR (CDCl_3 , 75 MHz) (peaks are listed only for major regioisomer): $\delta = 165.7, 138.0, 136.5, 132.0, 131.6, 128.9, 127.1, 42.7, 42.0, 21.1, 19.1$. MS (ESI) m/z : $[\text{M}]^+$ calcd for $\text{C}_{11}\text{H}_{14}\text{ClNO}$ 211.08, found 211.40. Anal. Calcd: C, 62.41; H, 6.67; N, 6.62. Found: C, 62.33; H, 6.57; N, 6.43. IR (cm^{-1}): 3282 (m), 3003 (w), 1645 (s), 1541 (m), 1466 (w), 1416 (w), 1362 (w), 1319 (w), 1225 (m), 1157 (w), 1061 (w), 1034 (w), 995 (w), 124 (w), 879 (w), 820 (m), 771 (w), 702 (s), 667 (m). R_f (hexane/EtOAc 4:1) = 0.3.

***N*-(2,4-Dimethylbenzyl)-2-cyanoacetamide (6g)**. Compound **6g** was synthesized according to TP 1 from 2-cyanoacetamide (168 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *m*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (387 mg, 96%, ratio of regioisomers 11:1). Mp: 136–137 °C. ¹H NMR (CDCl_3 , 400 MHz) (peaks only for major regioisomer listed): $\delta = 7.11$ (d, $J = 7.6$ Hz, 1H), 7.03–7.00 (m, 2H), 6.15 (bs, 1H), 4.44 (d, $J = 5.3$ Hz, 2H), 3.37 (s, 2H), 2.32 (s, 3H), 2.30 (s, 3H). ¹³C NMR (CDCl_3 , 101 MHz) (peaks not assigned to regioisomers): $\delta = 160.5, 138.3, 136.5, 131.8, 131.5, 129.1, 128.8, 127.2, 114.7, 52.3, 42.5, 25.9, 21.1, 19.9, 19.1$. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}$ 203.12, found 203.40. Anal. Calcd: C, 71.26;

H, 6.98; N, 13.85. Found: C, 71.28; H, 7.05; N, 13.66. IR (cm^{-1}): 3275 (m), 1647 (w), 1645 (s), 1571 (m), 1504 (w), 1468 (w), 1367 (m), 1365 (m), 1325 (w), 1232 (m), 1066 (w), 991 (w), 922 (w), 876 (w), 822 (m), 793 (m), 768 (w), 687 (m). R_f (hexane/EtOAc 1:1) = 0.5.

***N*-(2,4-Dimethylbenzyl)acetamide (6h).** Compound 6h was synthesized according to TP 1 from acetamide (29 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), *m*-xylene (0.18 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2 mL) at 100 °C for 8 h. Purification by chromatography (hexane/EtOAc 1:1) yielded the product as a colorless solid (45 mg, 51%, ratio of regioisomers 15:1). Mp: 110–112 °C. ^1H NMR (CDCl_3 , 400 MHz) (peaks are listed only for major regioisomer): δ = 7.11 (d, J = 7.6 Hz, 1H), 7.01–6.98 (m, 2H), 5.54 (bs, 1H), 4.39 (d, J = 5.3 Hz, 2H), 2.31 (s, 3H), 2.29 (s, 3H), 1.99 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) (peaks are not assigned to regioisomers): δ = 169.8, 137.7, 137.6, 136.5, 134.0, 132.9, 131.5, 129.0, 158.6, 128.1, 127.0, 41.8, 38.6, 23.3, 23.2, 21.1, 19.8, 19.0. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{16}\text{NO}$ 178.12, found 178.21. Anal. Calcd: C, 74.54; H, 8.53; N, 7.90. Found: C, 74.20; H, 8.65; N, 7.75. IR (cm^{-1}): 3289 (w), 3000 (w), 2920 (w), 2871 (w), 1689 (w), 1634 (s), 1538 (s), 1463 (s), 1377 (s), 1352 (w), 1300 (w), 1275 (s), 1215 (w), 1159 (w), 1124 (w), 1092 (m), 1037 (w), 998 (m), 951 (w), 886 (w), 816 (s), 770 (w), 713 (s), 617 (m), 598 (s), 573 (s), 552 (w), 508 (w), 467 (s). R_f (hexane/EtOAc 1:1) = 0.2.

***N*-(2,4-Dimethylbenzyl)-2,2,2-trimethylacetamide (6i).** Compound 6i was synthesized according to TP 1 from 2,2,2-trimethylacetamide (202 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *m*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (337 mg, 77%, ratio of regioisomers 17:1). Mp: 85–86 °C. ^1H NMR (CDCl_3 , 400 MHz) (peaks are listed only for major regioisomer): δ = 7.10 (d, J = 8 Hz, 1H), 7.01–6.98 (m, 2H), 5.67 (bs, 1H), 4.39 (d, J = 5 Hz, 2H), 2.31 (s, 3H), 2.28 (s, 3H), 1.21 (s, 9H). ^{13}C NMR (CDCl_3 , 101 MHz) (peaks are listed only for major regioisomer): δ = 178.1, 137.6, 136.6, 133.2, 131.5, 128.9, 126.9, 41.9, 38.9, 27.8, 21.1, 19.0. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{22}\text{NO}$ 220.17, found 220.80. Anal. Calcd: C, 76.67; H, 9.65; N, 6.39. Found: C, 76.42; H, 9.75; N, 6.11. IR (cm^{-1}): 3317 (m), 2954 (w), 1633 (s), 1539 (m), 1504 (w), 1425 (w), 1365 (w), 1296 (w), 1225 (w), 1213 (m), 1005 (m), 931 (w), 866 (w), 814 (m), 787 (m), 702 (w), 677 (m). R_f (hexane/EtOAc 1:1) = 0.4.

3-(2,4-Dimethylbenzyl)oxazolidin-2-one (6j). Compound 6j was synthesized according to TP 1 from oxazolidin-2-one (44 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), *m*-xylene (0.18 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol) in nitromethane (2 mL) at 100 °C for 6 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless oil (73 mg, 71%, ratio of regioisomers >5:1). ^1H NMR (CDCl_3 , 400 MHz): δ = 7.08 (d, J = 7.6 Hz, 1H), 7.02–6.98 (m, 2H), 4.42 (s, 2H), 4.30–4.26 (m, 2H), 3.38–3.34 (m, 2H), 2.31 (s, 3H), 2.31 (s, 3H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 158.3, 138.1, 136.9, 131.7, 130.7, 129.3, 126.9, 61.9, 46.5, 44.1, 21.1, 19.1. MS (ESI) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{12}\text{H}_{15}\text{NO}_2\text{Na}$ 228.10, found 227.80. Anal. Calcd: C, 70.22; H, 7.37; N, 6.82. Found: C, 69.94; H, 7.35; N, 6.74. IR (cm^{-1}): 3491 (w), 2919 (w), 1740 (s), 1616 (w), 1484 (m), 1424 (s), 1376 (m), 1355 (m), 1320 (w), 1252 (s), 1204 (m), 1185 (m), 1158 (m), 1119 (m), 1067 (s), 1034 (s), 975 (m), 954 (m), 921 (m), 878 (w), 833 (m), 803 (m), 778 (m), 760 (s), 728 (m), 717 (m), 693 (m), 652 (m), 581 (m), 538 (w), 490 (m). R_f (hexane/EtOAc 4:1) = 0.1.

***N*-(2,4-Dimethylbenzyl)-3-methyl-2-(1,3-dioxoisindolin-2-yl)butanamide (8).** Compound 8 was synthesized according to TP 1 from (S)-3-methyl-2-(1,3-dioxoisindolin-2-yl)butanamide (123 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), *m*-xylene (0.18 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2 mL) at 100 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless, very viscous foam (115 mg, 63%, mixture of regioisomers as determined by analytical HPLC 12:1). ^1H NMR (CDCl_3 , 400 MHz) (mixture of regioisomer and rotamers, peaks are not assigned): δ = 7.87–7.85 (m, 2H), 7.76–7.74 (m, 2H), 7.09 (d, J = 7.6 Hz, 1H), 7.03–7.02 (m, 1H), 6.98–6.94 (m, 2H), 4.49–4.42 (m, 2H), 4.35–4.31 (m, 1H), 2.85–2.85

(m, 1H), 2.29 (s, 3H), 2.26 (s, 3H), 1.10 (d, J = 6.7 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) (mixture of regioisomer and rotamers, peaks are not assigned): δ = 168.6, 168.6, 137.5, 136.3, 134.6, 132.7, 131.5, 131.5, 128.7, 128.6, 128.0, 127.0, 123.8, 63.3, 41.7, 38.6, 27.8, 21.1, 20.0, 19.8, 19.6, 19.1. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}_3$ 365.19, found 365.90. Anal. Calcd: C, 72.50; H, 6.64; N, 7.69. Found: C, 72.20; H, 6.60; N, 7.58. IR (cm^{-1}): 3329 (w), 2966 (m), 2926 (w), 2874 (w), 1770 (m), 1706 (s), 1660 (m), 1615 (m), 1530 (m), 1467 (m), 1381 (s), 1355 (s), 1332 (s), 1288 (m), 1225 (m), 1192 (m), 1172 (m), 1157 (m), 1123 (w), 1070 (s), 1014 (m), 988 (m), 961 (w), 927 (w), 888 (m), 817 (m), 791 (m), 716 (s), 660 (m), 627 (m), 575 (m), 560 (m), 530 (s). R_f (hexane/EtOAc 4:1) = 0.2.

***N*-(2,4,6-Trimethylbenzyl)benzamide (10a).** Compound 10a was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), mesitylene (0.83 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol, 5 mol %) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (371 mg, 73%). Mp: 151–152 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 7.73 (d, J = 8.1 Hz, 2H), 7.48 (t, J = 7.1 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H), 6.91 (s, 2H), 5.89 (bs, 1H), 4.64 (d, J = 4.4 Hz, 2H), 2.37 (s, 6H), 2.29 (s, 3H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.5, 137.9, 137.7, 136.6, 134.5, 131.6, 130.9, 129.7, 129.4, 128.7, 127.0, 38.9, 21.1, 19.8. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{20}\text{NO}$ 254.15, found 254.40. Anal. Calcd: C, 80.60; H, 7.56; N, 5.53. Found: C, 80.72; H, 7.65; N, 5.13. IR (cm^{-1}): 3296 (m), 1626 (s), 1578 (m), 1516 (s), 1471 (m), 1377 (w), 1269 (w), 1178 (w), 1076 (w), 1022 (w), 906 (w), 854 (m), 802 (m), 771 (w), 692 (s), 660 (w). R_f (hexane/EtOAc 4:1) = 0.3.

***N*-(2-Methoxybenzyl)benzamide (10b).** Compound 10b was synthesized according to TP 1 from benzamide (61 mg, 0.5 mmol), formalin (45 μL , 37 wt % solution in H_2O , 0.6 mmol), anisole (0.22 mL, 2.0 mmol, 4 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.1 mmol, 5 mol %) in nitromethane (2 mL) at 100 °C for 24 h. Purification by chromatography (hexane/EtOAc 9:1 \rightarrow 4:1) yielded the product as a yellow solid (82 mg, 68%, ratio of regioisomers 3:1). Mp: 110–111 °C. ^1H NMR (CDCl_3 , 400 MHz) (peaks are listed only for *para*-regioisomer): δ = 7.75–7.71 (m, 2H), 7.47–7.30 (m, 3H), 7.24–7.22 (m, 2H), 6.92–6.81 (m, 2H), 6.33 (bs, 1H), 4.55 (d, J = 5.5 Hz, 2H), 3.77 (s, 3H). ^{13}C NMR (CDCl_3 , 101 MHz) (peaks are not assigned to *ortho*- and *para*-isomer): δ = 167.4, 137.2, 136.1, 135.7, 134.6, 131.6, 130.1, 129.9, 129.5, 128.7, 128.7, 127.2, 127.1, 127.1, 125.9, 125.6, 44.1, 43.3, 20.6, 19.9, 19.5, 15.1. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ 242.12, found 242.40. Anal. Calcd: C, 74.67; H, 6.27; N, 5.81. Found: C, 74.44; H, 6.26; N, 5.63. IR (cm^{-1}): 1300 (w), 3223 (w), 3055 (w), 2924 (w), 2831 (w), 1630 (s), 1546 (w), 1539 (m), 1489 (m), 1460 (c), 1429 (w), 1350 (w), 1296 (m), 1238 (s), 1176 (m), 1109 (m), 1072 (w), 1032 (s), 172 (w), 926 (w), 812 (m), 752 (s), 694 (s), 667 (s). R_f (hexane/EtOAc 4:1) = 0.2.

***N*-(3-Chloro-4-methoxybenzyl)benzamide (10c).** Compound 10c was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 2-chloroanisole (0.76 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol, 5 mol %) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a yellow solid (462 mg, 84%). Mp: 117–118 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 7.79–7.77 (m, 2H), 7.51–7.47 (m, 1H), 7.43–7.39 (m, 2H), 7.35 (d, J = 2 Hz, 1H), 7.20 (dd, J_1 = 2 Hz, J_2 = 8 Hz, 1H), 6.87 (d, J = 8 Hz, 1H), 6.57 (bs, 1H), 4.54 (d, J = 6 Hz, 2H), 3.87 (s, 3H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.5, 154.6, 134.3, 131.8, 131.6, 129.9, 128.7, 127.5, 127.1, 122.7, 112.3, 56.3, 43.2. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{15}\text{ClNO}_2$ 276.08, found 276.00. Anal. Calcd: C, 65.34; H, 5.12; N, 5.08. Found: C, 65.05; H, 5.10; N, 4.91. IR (cm^{-1}): 3311 (w), 3242 (w), 3059 (w), 3010 (w), 2943 (w), 2927 (w), 2833 (w), 1626 (m), 1574 (w), 1541 (s), 1504 (m), 1462 (w), 1427 (w), 1354 (w), 1282 (s), 1182 (w), 1147 (w), 1063 (s), 1094 (m), 974 (m), 937 (w), 872 (m), 814 (m), 756 (m), 698 (s), 654 (w). R_f (hexane/EtOAc 4:1) = 0.1.

***N*-(3-Bromo-4-methoxybenzyl)benzamide (10d).** Compound 10d was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 2-bromoanisole (0.74 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol) in nitromethane (4

mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a yellow solid (563 mg, 88%). Mp: 112–113 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.79–7.77 (m, 2H), 7.52 (d, *J* = 7.5 Hz, 1H), 7.49–7.47 (m, 1H), 7.43–7.39 (m, 2H), 7.27–7.24 (m, 1H), 6.84 (d, *J* = 6.8 Hz, 1H), 6.58 (bs, 1H), 4.54 (d, *J* = 4.5 Hz, 2H), 3.87 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 167.5, 155.5, 134.3, 133.0, 132.1, 131.7, 128.7, 128.3, 127.1, 112.2, 111.9, 56.4, 43.1. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₅BrNO₂ 320.03, found 320.00. Anal. Calcd: C, 56.27; H, 4.41; N, 4.37; Found: C, 56.08; H, 4.39; N, 4.25. IR (cm⁻¹): 3307 (w), 3240 (w), 3055 (w), 3008 (w), 2964 (w), 2926 (w), 2831 (w), 1626 (m), 1539 (s), 1493 (s), 1460 (w), 1427 (w), 1402 (w), 1352 (w), 1261 (s), 1259 (s), 1180 (w), 1147 (w), 1061 (w), 1024 (m), 1022 (m), 170 (w), 137 (w), 885 (w), 860 (w), 814 (m), 754 (m), 698 (s), 667 (w). *R_f* (hexane/EtOAc 4:1) = 0.1.

***N*-(3-Iodo-4-methoxybenzyl)benzamide (10e)**. Compound 10e was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 2-iodoanisole (0.78 mL, 6.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (578 mg, 79%). Mp: 106–107 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.79–7.76 (m, 3H), 7.50 (t, *J* = 7.3 Hz, 1H), 7.43 (t, *J* = 7.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 1H), 6.78 (d, *J* = 8.4 Hz, 1H), 6.42 (bs, 1H), 4.54 (d, *J* = 5.7 Hz, 2H), 3.87 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 167.4, 157.8, 139.1, 134.4, 132.6, 131.8, 129.5, 128.8, 127.1, 111.1, 86.3, 56.6, 43.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₅INO₂ 368.01, found 368.40. Anal. Calcd: C, 49.07; H, 3.84; N, 3.81. Found: C, 49.03; H, 3.88; N, 3.66. IR (cm⁻¹): 3280 (w), 3030 (w), 2927 (w), 2831 (w), 1626 (s), 1578 (w), 1527 (m), 1485 (m), 1460 (m), 1400 (w), 1363 (w), 1288 (m), 1250 (m), 1225 (m), 1178 (w), 1144 (w), 1074 (w), 1047 (m), 1018 (m), 978 (w), 922 (w), 887 (w), 841 (w), 798 (m), 692 (s), 667 (m). *R_f* (hexanes/EtOAc 4:1) = 0.1.

***N*-(5-Chloro-2-methoxybenzyl)benzamide (10f)**. Compound 10f was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 4-chloroanisole (0.73 mL, 6.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (459 mg, 83%). Mp: 138–139 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.77 (d, *J* = 8.0 Hz, 2H), 7.48 (t, *J* = 7.0 Hz, 1H), 7.43 (t, *J* = 7.6 Hz, 2H), 7.31 (bd, *J* = 2.1 Hz, 1H), 7.22 (dd, *J* = 8.7, 2.3 Hz, 1H), 6.81 (d, 1H, *J* = 8.7 Hz), 6.65 (bs, 1H), 4.60 (d, *J* = 6.0 Hz, 2H), 3.86 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 167.3, 156.3, 134.7, 131.6, 129.7, 128.7, 128.6, 128.2, 127.1, 125.8, 111.7, 55.9, 39.5. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₅ClNO₂ 276.08, found 275.90. Anal. Calcd: C, 65.34; H, 5.12; N, 5.08. Found: C, 65.19; H, 5.07; N, 4.93. IR (cm⁻¹): 3269 (m), 3055 (w), 1624 (m), 1576 (m), 1543 (m), 1487 (m), 1443 (w), 1423 (w), 1352 (w), 1294 (w), 1254 (w), 1244 (m), 1176 (w), 1174 (w), 1126 (m), 1053 (w), 1049 (w), 1026 (m), 989 (w), 930 (w), 877 (w), 806 (m), 692 (s), 667 (w). *R_f* (hexane/EtOAc 4:1) = 0.1.

***N*-(5-Bromo-2-methoxybenzyl)benzamide (10g)**. Compound 10g was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 4-bromoanisole (0.75 mL, 6.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (494 mg, 77%). Mp: 123–124 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.78–7.75 (m, 2H), 7.53–7.40 (m, 4H), 7.38–7.35 (m, 1H), 6.76 (d, *J* = 9 Hz, 1H), 6.61 (bs, 1H), 4.61 (d, *J* = 6 Hz, 2H), 3.86 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 167.3, 156.8, 134.7, 132.6, 131.6, 131.6, 128.7, 128.6, 127.1, 113.1, 112.2, 55.9, 39.5. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₅BrNO₂ 320.03, found 320.00. Anal. Calcd: C, 56.27; H, 4.41; N, 4.37. Found: C, 56.15; H, 4.52; N, 4.27. IR (cm⁻¹): 3265 (w), 3055 (w), 1624 (m), 1576 (m), 1541 (m), 1489 (m), 1443 (w), 1421 (w), 1398 (w), 1350 (w), 1292 (w), 1244 (m), 1176 (w), 1174 (w), 1120 (w), 1055 (w), 1051 (w), 1024 (m), 987 (w), 131 (w), 856 (w), 806 (m), 692 (s), 667 (w). *R_f* (hexanes/EtOAc 4:1) = 0.2.

***N*-(5-Iodo-2-methoxybenzyl)benzamide (10h)**. Compound 10h was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 4-iodoanisole (1.40 g, 6.0

mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (465 mg, 64%). Mp: 117–118 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.78–7.74 (m, 2H), 7.63 (d, *J* = 2.3 Hz, 1H), 7.58–7.40 (m, 4H), 6.66 (d, *J* = 8.6 Hz, 1H), 6.59 (bs, 1H), 4.58 (d, *J* = 5.9 Hz, 2H), 3.86 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 167.3, 157.7, 138.4, 137.8, 134.7, 131.6, 129.0, 128.7, 127.1, 112.9, 83.1, 55.8, 39.4. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₅INO₂ 368.01, found 368.40. Anal. Calcd: C, 49.07; H, 3.84; N, 3.81; Found: C, 49.18; H, 3.89; N, 3.69. IR (cm⁻¹): 3267 (w), 3061 (w), 3008 (w), 2947 (w), 2835 (w), 2158 (w), 1992 (w), 1633 (s), 1551 (w), 1539 (s), 1495 (f), 458 (m), 1433 (m), 1360 (w), 1309 (m), 1279 (m), 1263 (m), 1242 (w), 1215 (s), 1118 (m), 1151 (w), 1059 (w), 1045 (m), 1020 (m), 993 (w), 924 (w), 906 (w), 879 (m), 825 (m), 795 (s), 710 (s), 665 (w). *R_f* (hexanes/EtOAc 4:1) = 0.1.

***N*-(3,6-Dimethoxybenzyl)benzamide (10i)**. Compound 10i was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 1,4-dimethoxybenzene (1.128 g, 8.0 mmol, 4 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 5 mol %) in nitromethane (4 mL) at 80 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a yellow solid (0.18 g, 42%). Mp: 101–102 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.76 (d, *J* = 8 Hz, 2H), 7.48 (t, *J* = 7 Hz, 1H), 7.41 (t, *J* = 7 Hz, 2H), 6.94 (d, *J* = 2 Hz, 1H), 6.84–6.78 (m, 2H), 6.68 (bs, 1H), 4.62 (d, *J* = 6 Hz, 2H), 3.84 (s, 3H), 3.76 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 167.1, 153.6, 151.8, 134.7, 131.3, 128.5, 127.2, 126.9, 115.9, 113.3, 111.4, 55.9, 55.8, 40.1. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₁₈NO₃ 272.1, found 272.4. Anal. Calcd: C, 70.83; H, 6.32; N, 5.16. Found: C, 70.92; H, 6.21; N, 5.11. IR (cm⁻¹): 3267 (m), 3062 (w), 3008 (w), 2949 (w), 2833 (w), 2154 (w), 1996 (w), 1952 (w), 1633 (s), 1579 (w), 1539 (s), 1495 (s), 1458 (m), 1431 (m), 1360 (w), 1309 (s), 1279 (m), 1242 (w), 1215 (s), 1180 (m), 1149 (w), 1115 (m), 1059 (w), 1045 (s), 1020 (s), 993 (m), 924 (w), 874 (w), 879 (m), 825 (m), 795 (s), 710 (s), 667 (w). *R_f* (Hexane/EtOAc 4:1) = 0.1.

Ethyl 3-((Benzamido)methyl)-4-methoxybenzoate (10j). Compound 10j was synthesized according to TP 1 from benzamide (61 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), ethyl-4-methoxybenzoate (0.25 mL, 1.5 mmol, 3.0 equiv), and Bi(OTf)₃ (16 mg, 0.025 mmol) in nitromethane (2 mL) at 100 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (135 mg, 87%). Mp: 127–129 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 8.03–7.99 (m, 2H), 7.78–7.75 (m, 2H), 7.50–7.46 (m, 1H), 7.42–7.40 (m, 2H), 6.92 (d, *J* = 8.5 Hz, 1H), 6.60 (bs, 1H), 4.67 (d, *J* = 5.9 Hz, 2H), 4.33 (q, *J* = 7.1 Hz, 2H), 3.94 (s, 3H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ = 167.4, 166.4, 161.4, 134.8, 131.5, 131.4, 131.2, 128.7, 127.1, 126.3, 123.2, 110.1, 60.9, 55.9, 39.9, 14.5. MS (ESI) *m/z*: [M + Na]⁺ calcd for C₁₈H₁₉NO₄Na 336.12, found 336.25. HRMS (MALDI) *m/z*: [M + H]⁺ calcd for C₁₈H₂₀NO₄ 314.1387, found 314.1389. IR (cm⁻¹): 3279 (w), 2978 (w), 1710 (s), 1626 (s), 1611 (m), 1578 (m), 1549 (m), 1504 (m), 1491 (w), 1462 (w), 1446 (w), 1413 (w), 1361 (m), 1314 (s), 1264 (s), 1174 (m), 1125 (s), 1050 (w), 1022 (s), 993 (w), 931 (w), 909 (w), 875 (w), 832 (m), 768 (s), 695 (s), 672 (m), 628 (m), 607 (w), 539 (w), 510 (w). *R_f* (hexane/EtOAc 4:1) = 0.1.

***N*-(4-Methyl-3-pivalamido)benzamide (10k)**. Compound 10k was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *N*-*o*-tolylpivalamide (1.15 g, 6.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (430 mg, 66%). Mp: 170–171 °C. ¹H NMR (CDCl₃, 400 MHz): δ = 7.78 (d, *J* = 7.8 Hz, 3H), 7.49 (t, *J* = 7.2 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 2H), 7.23 (bs, 1H), 7.18–7.16 (m, 2H), 6.45 (bs, 1H), 4.56 (d, *J* = 5.6 Hz, 2H), 2.23 (s, 3H), 1.34 (s, 9H). ¹³C NMR (CDCl₃, 101 MHz): δ = 176.7, 167.4, 135.4, 134.9, 134.5, 131.7, 130.3, 129.6, 128.7, 127.1, 126.5, 123.5, 43.9, 39.9, 27.9, 17.8. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₂₅N₂O₂ 325.19, found 325.60. HRMS (MALDI) *m/z*: [M + H]⁺ calcd for C₂₀H₂₅N₂O₂ 325.1916, found 325.1914. IR (cm⁻¹): 3307 (b), 2953 (w), 1643 (s), 1558 (w), 1541 (m), 1506 (s), 1417 (w), 1309 (w), 1221 (w), 1178 (w),

1051 (w), 1005 (w), 984 (w), 980 (w), 930 (w), 849 (w), 802 (m), 737 (w), 694 (s), 667 (w). R_f (hexane/EtOAc 1:1) = 0.3.

***N*-(2,5-Dimethylbenzyl)benzamide (10l)**. Compound **10l** was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), *p*-xylene (0.74 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol, 5 mol %) in nitromethane (4 mL) at 100 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (177 mg, 37%). Mp: 113–114 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 7.79–7.78 (m, 2H), 7.52–7.48 (m, 1H), 7.45–7.40 (m, 2H), 7.12–7.09 (m, 2H), 7.04 (d, J = 8 Hz, 1H), 6.22 (bs, 1H), 4.61 (d, J = 5 Hz, 2H), 2.34 (s, 3H), 2.32 (s, 3H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.1, 135.8, 135.5, 134.4, 133.4, 131.5, 130.6, 129.6, 129.6, 128.6, 126.9, 42.4, 20.9, 18.6. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{18}\text{NO}$ 240.1, found 240.4. Anal. Calcd: C, 80.30; H, 7.16; N, 5.85. Found: C, 80.28; H, 7.05; N, 5.76. IR (cm^{-1}): 2290 (m), 2912 (w), 1626 (s), 1578 (m), 1531 (s), 1460 (w), 1360 (w), 1308 (m), 1298 (w), 1236 (w), 1180 (w), 1147 (w), 1074 (w), 1053 (w), 1028 (w), 1001 (w), 970 (w), 922 (w), 864 (w), 856 (w), 814 (m), 712 (w), 694 (s), 669 (w). R_f (hexane/EtOAc 4:1) = 0.3.

***N*-(5-Bromo-2-hydroxybenzyl)benzamide (10m)**. Compound **10m** was synthesized according to TP 1 from benzamide (61 mg, 0.5 mmol), paraformaldehyde (19 mg, 0.6 mmol), 4-bromophenol (346 mg, 2.0 mmol, 4 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol) in nitromethane (2 mL) at 80 °C for 24 h. Purification by chromatography (hexane/EtOAc 9:1 \rightarrow 4:1) yielded the product as a colorless solid (104 mg, 68%). Mp: 154–156 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 9.67 (bs, 1H), 7.78–7.76 (m, 2H), 7.56–7.52 (m, 1H), 7.46–7.42 (m, 2H), 7.31–7.29 (m, 2H), 6.98 (bs, 1H), 6.85 (d, J = 8.6 Hz, 1H), 4.50 (d, J = 6.6 Hz, 2H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 170.0, 155.4, 133.4, 133.0, 132.7, 132.5, 129.0, 127.4, 126.3, 120.2, 111.5, 40.8. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{13}\text{BrNO}_2$ 306.01, found 306.05. Anal. Calcd: C, 54.92; H, 3.95; N, 4.58. Found: C, 54.58; H, 3.93; N, 4.41. IR (cm^{-1}): 3343 (w), 2598 (w), 1682 (w), 1615 (w), 1545 (s), 1481 (s), 1392 (m), 1352 (w), 1310 (m), 1268 (m), 1254 (s), 1222 (m), 1180 (w), 1117 (m), 1081 (w), 1032 (w), 1002 (w), 972 (w), 932 (w), 907 (w), 817 (s), 789 (m), 738 (w), 711 (s), 690 (s), 630 (s), 551 (m), 516 (s), 492 (w). R_f (hexane/EtOAc 4:1) = 0.1.

***N*-(5-Methylthiophene-2-yl)methylbenzamide (10o)**. Compound **10o** was synthesized according to TP 1 from benzamide (73 mg, 0.6 mmol), formalin (37 μL , 37 wt % solution in H_2O , 0.5 mmol), 2-methylthiophene (0.15 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2 mL) at 25 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a yellow solid (74 mg, 64%, mixture of regioisomers 12:1). Mp: 105–107 °C. ^1H NMR (CDCl_3 , 400 MHz) (peaks are listed only for major regioisomer): δ = 7.81–7.75 (m, 2H), 7.52–7.48 (m, 1H), 7.46–7.41 (m, 2H), 6.82 (bd, J = 3.3 Hz, 1H), 6.61–6.60 (m, 1H), 6.36 (s, 1H), 4.73 (d, J = 5.5 Hz, 2H), 2.46 (s, 3H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.2, 140.2, 138.4, 134.4, 131.7, 128.7, 127.1, 126.3, 125.0, 39.3, 15.5. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{14}\text{NOS}$ 232.08, found 232.60. Anal. Calcd: C, 67.50; H, 5.66; N, 6.06; S, 13.86. Found: C, 67.47; H, 5.52; N, 5.91; S, 14.14. IR (cm^{-1}): 3345 (m), 3060 (w), 2917 (w), 2856 (w), 1630 (s), 1602 (m), 1576 (m), 1538 (s), 1490 (s), 1445 (m), 1424 (m), 1350 (m), 1325 (m), 1294 (s), 1260 (m), 1216 (m), 1190 (m), 1153 (m), 1101 (w), 1075 (m), 1049 (m), 1032 (m), 1003 (w), 976 (m), 930 (w), 866 (m), 808 (m), 797 (s), 742 (m), 711 (s), 686 (s), 662 (m), 600 (s), 556 (s), 499 (m). R_f (hexane/EtOAc 4:1) = 0.2.

***N*-(5-Bromothiophene-3-yl)benzamide (10p)**. Compound **10p** was synthesized according to TP 1 from benzamide (242 mg, 2.0 mmol), paraformaldehyde (72 mg, 2.4 mmol), 2-bromothiophene (0.6 mL, 6.0 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol) in nitromethane (4 mL) at 80 °C for 16 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a yellow solid (558 mg, 94%). Mp: 117–118 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 7.79–7.78 (m, 1H), 7.77–7.76 (m, 1H), 7.54–7.48 (m, 1H), 7.45–7.40 (m, 2H), 6.90 (d, J = 4 Hz, 1H), 6.79–6.78 (m, 1H), 6.53 (bs, 1H), 4.71 (d, J = 6 Hz, 2H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.4, 142.8, 134.0, 131.9, 129.7, 128.8, 127.1, 126.7, 112.0, 39.2. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{11}\text{BrNOS}$ 295.97, found 295.90. HRMS (MALDI) m/z : $[\text{M} + \text{H}]^+$ calcd for

$\text{C}_{12}\text{H}_{11}\text{BrNOS}$ 295.9745, found 295.9748. IR (cm^{-1}): 3278 (w), 3055 (w), 2924 (w), 1626 (m), 1601 (w), 1552 (w), 1531 (s), 1489 (m), 1441 (m), 1417 (m), 1354 (w), 1292 (m), 1255 (e), 1205 (m), 1142 (m), 1051 (w), 1047 (m), 182 (m), 157 (m), 330 (w), 783 (m), 739 (m), 688 (s). R_f (hexane/EtOAc 4:1) = 0.3.

***N*-(5-Chlorothiophene-2-yl)methylbenzamide (10q)**. Compound **10q** was synthesized according to TP 1 from benzamide (61 mg, 0.6 mmol), formalin (45 μL , 37 wt % solution in H_2O , 0.6 mmol), 2-chlorothiophene (0.14 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2 mL) at 40 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (86 mg, 69%). Mp: 109–110 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 7.78–7.76 (m, 2H), 7.53–7.51 (m, 1H), 7.43 (t, J = 7.5 Hz, 2H), 6.80 (d, J = 3.7 Hz, 1H), 6.76 (d, J = 3.7 Hz, 1H), 6.51 (bs, 1H), 4.70 (d, J = 5.8 Hz, 2H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.4, 139.9, 134.1, 131.9, 129.9, 128.8, 127.1, 125.9, 125.7, 39.3. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{11}\text{ClNOS}$ 252.02, found 252.50. HRMS (MALDI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{11}\text{ClNOS}$ 252.0244 [M + H]⁺, found 252.0243. IR (cm^{-1}): 3317 (w), 1683 (w), 1629 (s), 1602 (m), 1577 (m), 1550 (s), 1534 (s), 1490 (s), 1453 (m), 1418 (m), 1356 (w), 1296 (m), 1258 (m), 1207 (m), 1189 (w), 1161 (w), 1146 (w), 1057 (w), 1035 (w), 1026 (w), 996 (m), 967 (m), 929 (w), 792 (m), 739 (w), 689 (s), 664 (m), 641 (m), 616 (m), 565 (m), 533 (w), 482 (w). R_f (hexane/EtOAc 4:1) = 0.2.

***N*-(1-Tosyl-1H-indol-3-yl)methylbenzamide (10r)**. Compound **10r** was synthesized according to TP 1 from benzamide (61 mg, 0.6 mmol), formalin (45 μL , 37 wt % solution in H_2O , 0.6 mmol), 1-tosyl-1H-indole (407 mg, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol) in nitromethane (2 mL) at 40 °C for 24 h. Purification by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (155 mg, 76%, ratio of regioisomers 14:1). Mp: 157–159 °C. ^1H NMR (CDCl_3 , 400 MHz) (peaks only for major isomer listed): δ = 7.99 (d, J = 8.3 Hz, 1H), 7.79–7.74 (m, 4H), 7.61–7.56 (m, 2H), 7.51–7.47 (m, 1H), 7.41 (t, J = 7.5 Hz, 2H), 7.36–7.32 (m, 1H), 7.23 (d, J = 8.6 Hz, 3H), 6.29 (bs, 1H), 4.77 (d, J = 5.5 Hz, 2H), 2.33 (d, J = 8.5 Hz, 3H). ^{13}C NMR (CDCl_3 , 101 MHz) (peaks are not assigned to regioisomers): δ = 167.5, 145.3, 135.5, 135.4, 134.3, 131.8, 130.1, 129.7, 128.8, 127.1, 127.0, 125.3, 124.6, 123.6, 119.9, 119.4, 113.9, 35.3, 21.7. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{21}\text{N}_2\text{O}_3\text{S}$ 405.13, found 405.70. Anal. Calcd: C, 68.30; H, 4.98; N, 6.93; S, 7.93. Found: C, 67.90; H, 4.91; N, 6.63; S, 7.75. IR (cm^{-1}): 1639 (m), 1602 (w), 1578 (w), 1537 (m), 1490 (m), 1447 (m), 1424 (w), 1371 (s), 1327 (w), 1295 (m), 1273 (m), 1252 (m), 1207 (m), 1187 (m), 1172 (s), 1119 (s), 1093 (m), 1047 (m), 1016 (m), 987 (m), 963 (m), 805 (m), 788 (m), 757 (s), 749 (m), 711 (m), 695 (m), 665 (s), 622 (m), 589 (s), 582 (s), 568 (s), 543 (s), 533 (s), 494 (m). R_f (hexane/EtOAc 4:1) = 0.1.

***N*-(Benzofuran-3-yl)benzamide (10s)**. Compound **10s** was synthesized according to TP 1 from benzamide (61 mg, 0.5 mmol), formalin (45 μL , 37 wt % solution in H_2O , 0.6 mmol), benzofuran (0.16 mL, 1.5 mmol, 3.0 equiv), and $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %) in nitromethane (2 mL) at 40 °C for 24 h. Purification by chromatography (cyclohexane/EtOAc 9:1 \rightarrow 4:1) yielded the product as a white solid (88 mg, 70%, ratio of regioisomers: 24:1). Mp: 127–128 °C. ^1H NMR (CDCl_3 , 400 MHz) (peaks are listed only for major regioisomer): δ = 7.81 (d, J = 8 Hz, 2H), 7.52–7.51 (m, 2H), 7.45–7.43 (m, 3H), 7.27–7.21 (m, 2H), 6.67 (s, 1H), 6.63 (bs, 1H), 4.79 (d, J = 6 Hz, 2H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 167.5, 155.1, 154.0, 134.2, 131.9, 128.8, 128.4, 127.2, 124.4, 123.0, 121.2, 111.3, 104.6, 37.6. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{NO}_2$ 252.10, found 252.40. HRMS (MALDI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{NO}_2$ 252.1019, found 252.1021. IR (cm^{-1}): 3304 (w), 3049 (w), 1626 (m), 1578 (w), 1525 (m), 1489 (m), 1448 (m), 1361 (w), 1279 (m), 254 (w), 1219 (w), 1178 (m), 1076 (w), 1051 (w), 984 (w), 980 (m), 935 (m), 873 (m), 800 (m), 731 (w), 727 (w), 692 (s). R_f (hexane/EtOAc 4:1) = 0.2.

***N,N'*-Methylene-bis-benzamide (11)**. Benzamide (3.00 g, 25 mmol, 2.0 equiv), paraformaldehyde (0.41 g, 12 mmol, 1.0 equiv), and H_2SO_4 (1 drop) in toluene (25 mL) were refluxed in a Dean–Stark apparatus. After being cooled to 0 °C the mixture was filtrated and the crude residue washed with toluene and dried in high vacuum. The product was obtained as a colorless solid, sufficiently pure for further transformations

(2.77 g, 91%). ¹H NMR (DMSO, 250 MHz): δ = 9.07–9.02 (m, 2H), 7.92–7.89 (m, 4H), 7.53–7.42 (m, 6H), 4.89–4.85 (m, 2H). Analytical data are consistent with the literature.²⁷

***N*-(Hydroxymethylene)benzamide (12)**. A 50 mL round-bottom flask was charged with benzamide (7.00 g, 46.0 mmol, 1.2 equiv), K₂CO₃ (0.20 g, 1.5 mmol, 3 mol %), and formalin (4.1 mL, 37 wt % solution in H₂O, 55.0 mmol, 1.0 equiv) in H₂O (7 mL). The reaction was stirred at 50 °C until everything was dissolved. After being cooled to rt, the mixture was filtrated. Purification of the crude residue by recrystallization from ethanol yielded the product as a colorless solid, sufficiently pure for further transformations (1.33 g, 19%). ¹H NMR (DMSO, 250 MHz): δ = 9.14–9.10 (m, 1H), 7.88 (d, *J* = 8 Hz, 2H), 7.54–7.44 (m, 3H), 5.66 (bs, 1H), 4.72–4.70 (m, 2H). Analytical data are consistent with literature.⁴¹

***N*-(2-Methyl-1-propen-1-yl)benzamide (14)**. Compound 14 was isolated during the attempted preparation of *N*-(2-methyl-1-(2,4,6-trimethylbenzyl)propyl)benzamide. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), isobutyraldehyde (42 μ L, 0.5 mmol), mesitylene (0.21 mL, 1.5 mmol, 3.0 equiv), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCE (2 mL). The reaction mixture was stirred at 80 °C for 16 h. After being cooled to room temperature, the reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by column chromatography (hexane/EtOAc 4:1) afforded 14 (66 mg, 75%) as a colorless solid. ¹H NMR (CDCl₃, 250 MHz): δ = 7.80–7.77 (m, 2H), 7.54–7.41 (m, 4H), 6.76–6.72 (m, 1H), 1.77 (s, 3H), 1.71 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 164.3, 134.4, 131.8, 128.8, 127.1, 117.5, 116.5, 22.7, 16.8. Analytical data are consistent with literature.⁴²

***N*-(2-Methyl-1-(5-methylfuran-2-yl)propyl)benzamide (17)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), isobutyraldehyde (42 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a colorless solid (78 mg, 61%). Mp: 82–84 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.81–7.77 (m, 2H), 7.53–7.41 (m, 3H), 6.42 (bd, *J* = 8.9 Hz, 1H), 6.08 (d, *J* = 3.0 Hz, 1H), 5.89–5.87 (m, 1H), 5.09–5.03 (m, 1H), 2.27 (s, 3H), 2.24–2.17 (m, 1H), 1.02 (d, *J* = 6.8 Hz, 3H), 0.93 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.8, 151.9, 151.4, 134.9, 131.6, 128.7, 127.1, 107.8, 106.1, 53.4, 32.6, 19.4, 19.0, 13.7. MS (ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₂₀NO₂ 258.2, found 258.5. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₁₆H₁₉NO₂K 296.1048, found 296.1047. IR (cm⁻¹): 3337 (w), 2966 (m), 2923 (m), 1639 (s), 1603 (w), 1580 (m), 1565 (m), 1533 (s), 1492 (m), 1463 (m), 1383 (w), 1361 (m), 1346 (m), 1311 (m), 1269 (m), 1219 (m), 1149 (m), 1111 (w), 1055 (m), 1033 (s), 1018 (m), 1002 (m), 948 (w), 883 (w), 821 (w), 802 (w), 787 (s), 772 (m), 716 (m), 694 (s), 666 (m), 627 (m), 601 (m), 510 (w), 471 (w). *R_f* (hexane/EtOAc 4:1): 0.3.

***N*-(1-(5-Methylfuran-2-yl)-3-phenylpropyl)benzamide (19a)**. A 10 mL screw-cap vial was charged with benzamide (73 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μ L, 0.5 mmol), Bi(OTf)₃ (7 mg, 0.025 mmol, 2 mol %), and DCM (2 mL). The mixture was cooled to 0 °C, and 2-methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) was added. The reaction was stirred at rt for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 4:1) yielded the product as a yellow oil (130 mg, 81%). ¹H NMR (CDCl₃, 300 MHz): δ = 7.75–7.72 (m, 2H), 7.51–7.39 (m, 3H), 7.31–7.26 (m, 2H), 7.21–7.19 (m, 3H), 6.40 (bd, *J* = 8.5 Hz, 1H), 6.14 (d, *J* = 3.0 Hz, 1H), 5.92–5.90 (m, 1H), 5.33 (q, *J* = 7.3 Hz, 1H), 2.75–2.65 (m, 2H), 2.30–2.21 (m, 5H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.6, 152.2, 151.8, 141.5, 134.6, 131.6, 128.6, 128.6, 128.5, 127.1, 126.1, 107.6, 106.2, 47.8, 35.8, 32.5, 13.7. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₂₂NO₂ 320.2, found 320.5. HRMS

(MALDI) *m/z*: [M + K]⁺ calcd for C₂₁H₂₁NO₂K 358.1204, found 358.1207. IR (cm⁻¹): 3322 (w), 1634 (s), 1602 (w), 1577 (m), 1527 (s), 1487 (m), 1454 (m), 1437 (m), 1354 (w), 1327 (m), 1289 (m), 1217 (m), 1200 (w), 1158 (w), 1093 (w), 1074 (m), 1062 (w), 1020 (m), 951 (m), 841 (w), 793 (m), 787 (m), 766 (m), 754 (w), 743 (m), 706 (s), 691 (s), 666 (m), 629 (m), 615 (m), 579 (m), 545 (m), 510 (w), 490 (m), 468 (w). *R_f* (hexane/EtOAc 4:1): 0.3.

***N*-(1-(5-Methylfuran-2-yl)-2-phenylpropyl)benzamide (19b)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), 2-phenylpropionaldehyde (68 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 1 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a yellow solid (85 mg, 53%, ratio of diastereomers: 7:1). Mp: 132–134 °C. ¹H NMR (CDCl₃, 300 MHz) (peaks are listed only for major diastereomer): δ = 7.79–7.75 (m, 2H), 7.51–7.41 (m, 3H), 7.27–7.19 (m, 3H), 7.10–7.07 (m, 2H), 6.47 (bd, *J* = 9.2 Hz, 1H), 5.85 (d, *J* = 3.1 Hz, 1H), 5.78–5.77 (m, 1H), 5.45 (q, *J* = 9.2, 7.7 Hz, 1H), 3.34 (quint, *J* = 7.2 Hz, 1H), 2.20 (s, 3H), 1.42 (d, *J* = 7.1 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) (peaks are listed only for major diastereomer): δ = 166.6, 151.3, 150.6, 142.7, 134.7, 131.7, 128.7, 128.2, 128.7, 127.1, 126.8, 108.7, 106.1, 53.1, 44.2, 18.2, 13.6. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₂₂NO₂ 320.2, found 320.6. HRMS (MALDI) *m/z*: [M + Na]⁺ calcd for C₂₁H₂₁NO₂Na 342.1465, found 342.1465. IR (cm⁻¹): 3300 (w), 3061 (w), 3029 (w), 2970 (w), 2923 (w), 1635 (s), 1602 (w), 1579 (w), 1530 (m), 1489 (m), 1453 (m), 1375 (s), 1330 (m), 1288 (w), 1220 (w), 1183 (w), 1144 (w), 1075 (w), 1050 (w), 1020 (m), 1000 (w), 965 (w), 950 (w), 910 (w), 866 (w), 784 (m), 762 (m), 698 (s), 666 (m), 616 (w), 551 (w). *R_f* (hexane/EtOAc 4:1): 0.4.

***N*-(1-(5-Methylfuran-2-yl)-2-phenylethyl)benzamide (19c)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), 2-phenylacetaldehyde (59 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a colorless solid (68 mg, 45%). Mp: 130–132 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.73–7.70 (m, 2H), 7.50–7.38 (m, 3H), 7.28–7.18 (m, 3H), 7.14–7.11 (m, 2H), 6.37 (bd, *J* = 8.3 Hz, 1H), 5.96 (d, *J* = 3.1 Hz, 1H), 5.86–5.85 (m, 1H), 5.51 (q, *J* = 7.8 Hz, 1H), 3.31–3.17 (m, 2H), 2.30 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.6, 151.7, 151.5, 137.3, 134.6, 131.7, 129.5, 128.7, 128.5, 127.1, 126.8, 107.9, 106.3, 49.2, 40.4, 13.8. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₂₀NO₂ 306.15, found 306.00. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₀H₁₉NO₂K 344.1047, found 344.1047. IR (cm⁻¹): 3300 (w), 3062 (w), 1637 (s), 1603 (w), 1579 (m), 1533 (s), 1490 (s), 1454 (w), 1296 (w), 1219 (w), 1081 (w), 1038 (w), 1026 (w), 787 (w), 697 (s). *R_f* (hexane/EtOAc 4:1): 0.3.

***N*-(2-(Benzyloxy)-1-(5-methylfuran-2-yl)ethyl)benzamide (19d)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), (benzyloxy)acetaldehyde (72 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (4 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a yellow oil (129 mg, 77%). ¹H NMR (CDCl₃, 300 MHz): δ = 7.77–7.74 (m, 2H), 7.46–7.36 (m, 3H), 7.29–7.22 (m, 5H), 6.70 (bd, *J* = 8.2 Hz, 1H), 6.15 (d, *J* = 3.1 Hz, 1H), 5.89–5.88 (m, 1H), 5.49–5.43 (m, 1H), 4.53 (d, *J* = 2.4 Hz, 2H), 3.91–3.86 (m, 1H), 3.81–3.76 (m, 1H), 2.24 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz):

δ = 166.8, 151.7, 150.6, 138.0, 134.4, 131.7, 128.6, 128.5, 127.8, 127.8, 127.2, 108.0, 106.4, 73.2, 70.6, 47.7, 13.7. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{21}H_{22}NO_3$ 336.2, found 336.3. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{21}H_{21}NO_3K$ 374.1153, found 374.1156. IR (cm^{-1}): 3321 (w), 3063 (w), 3031 (w), 2923 (w), 2866 (w), 1722 (m), 1642 (s), 1602 (m), 1579 (m), 1521 (s), 1486 (m), 1453 (m), 1362 (m), 1270 (m), 1248 (m), 1208 (m), 1177 (m), 1158 (m), 1098 (s), 1072 (s), 1026 (s), 1001 (m), 929 (m), 800 (m), 737 (m), 711 (s), 695 (s), 609 (m), 571 (m). R_f (hexane/EtOAc 4:1): 0.2.

***N*-(1-(5-Methylfuran-2-yl)propyl)benzamide (19e)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), propanal (37 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (4 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 22 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a yellow oil (65 mg, 53%). ¹H NMR (CDCl₃, 300 MHz): δ = 7.80–7.76 (m, 2H), 7.52–7.38 (m, 3H), 6.38 (bd, J = 8.3 Hz, 1H), 6.11 (d, J = 3.0 Hz, 1H), 5.89–5.88 (m, 1H), 5.16 (q, J = 7.4 Hz, 1H), 2.27 (s, 3H), 1.98–1.87 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.7, 152.4, 151.7, 134.8, 131.6, 128.7, 127.1, 107.8, 106.2, 49.3, 27.4, 13.7, 10.6. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{15}H_{18}NO_2$ 244.13, found 244.00. HRMS (MALDI) m/z : $[M - H]^+$ calcd for $C_{15}H_{16}NO_2$ 242.1181, found 242.1177. IR (cm^{-1}): 3311 (w), 2968 (w), 2935 (w), 2876 (w), 1726 (w), 1635 (s), 1602 (w), 1578 (m), 1531 (s), 1489 (m), 1458 (w), 1447 (w), 1385 (w), 1329 (m), 1297 (m), 1244 (w), 1216 (w), 1186 (w), 1153 (w), 1125 (w), 1103 (w), 1074 (w), 1021 (m), 1000 (w), 949 (w), 931 (w), 855 (w), 785 (m), 768 (m), 710 (m), 691 (s), 662 (m), 615 (m), 571 (w), 550 (w). R_f (hexane/EtOAc 4:1): 0.4. Analytical data are consistent with literature.⁴³

***N*-(2-Methyl-1-(5-methylfuran-2-yl)butyl)benzamide (19f)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), 2-methylbutyraldehyde (56 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (4 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a yellow oil (98 mg, 72%, ratio of diastereomers 2:1). ¹H NMR (CDCl₃, 300 MHz) (peaks are not assigned to diastereomers): δ = 7.80–7.77 (m, 2H), 7.53–7.40 (m, 3H), 6.46–6.37 (m, 1H), 6.07 (t, J = 3.5 Hz, 1H), 5.89–5.87 (m, 1H), 5.23–5.10 (m, 1H), 2.27 (s, 3H), 2.02–1.93 (m, 1H), 1.59–1.40 (m, 1H), 1.22–1.11 (m, 1H), 1.00–0.89 (m, 6H). ¹³C NMR (CDCl₃, 75 MHz) (peaks are not assigned to diastereomers): δ = 166.8, 166.7, 152.2, 151.8, 151.4, 134.9, 131.6, 128.7, 128.7, 127.1, 107.9, 107.5, 106.1, 52.3, 52.0, 38.9, 26.3, 25.8, 15.8, 15.3, 13.7, 11.7, 11.6. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{17}H_{22}NO_2$ 272.2, found 272.4. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{17}H_{21}NO_2K$ 310.1204, found 310.1204. IR (cm^{-1}): 3300 (w), 3061 (w), 2963 (w), 2925 (w), 2876 (w), 1635 (s), 1603 (w), 1579 (m), 1529 (s), 1488 (m), 1462 (m), 1381 (w), 1328 (m), 1287 (m), 1261 (m), 1220 (m), 1187 (w), 1142 (w), 1075 (w), 1020 (m), 1001 (w), 964 (w), 951 (w), 911 (w), 877 (w), 783 (s), 731 (m), 709 (s), 692 (s), 666 (m), 616 (m), 573 (m), 521 (w). R_f (hexane/EtOAc 4:1): 0.4.

***N*-(3-Methyl-1-(5-methylfuran-2-yl)butyl)benzamide (19g)**. A 10 mL flask was charged with benzamide (72 mg, 0.6 mmol), isovaleraldehyde (55 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (4 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1 → 4:1) yielded the product as a colorless solid (90 mg, 66%). Mp: 111–113 °C. ¹H

NMR (CDCl₃, 300 MHz): δ = 7.79–7.76 (m, 2H), 7.51–7.38 (m, 3H), 6.31 (bd, J = 8.5 Hz, 1H), 6.11 (d, J = 3.0 Hz, 1H), 5.88–5.87 (m, 1H), 5.34 (q, J = 16.2, 7.8 Hz, 1H), 2.26 (s, 3H), 1.82–1.75 (m, 2H), 1.68–1.54 (m, 1H), 1.00–0.94 (m, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.5, 152.9, 151.6, 134.7, 131.6, 128.7, 127.1, 107.1, 106.2, 46.2, 43.4, 25.2, 22.7, 22.7, 13.7. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{17}H_{22}NO_2$ 272.2, found 272.8. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{17}H_{21}NO_2K$ 310.1204, found 310.1205. IR (cm^{-1}): 3300 (w), 3062 (w), 2955 (w), 2925 (w), 2869 (w), 1634 (s), 1603 (w), 1579 (m), 1532 (s), 1490 (m), 1469 (m), 1448 (w), 1385 (w), 1367 (w), 1331 (m), 1289 (m), 1220 (m), 1187 (w), 1148 (w), 1076 (w), 1037 (w), 1021 (m), 1001 (w), 953 (w), 937 (w), 869 (w), 782 (s), 693 (s), 666 (m), 647 (m), 616 (m), 555 (w). R_f (hexane/EtOAc 4:1): 0.5.

***N*-(1-(5-Methylfuran-2-yl)-3-phenylpropyl)acrylamide (20a)**. A 10 mL flask was charged with acrylamide (76 mg, 1.0 mmol), 3-phenylpropionaldehyde (69 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (59 μ L, 0.6 mmol, 1.2 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (78 mg, 59%). Mp: 76–78 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.29–7.24 (m, 2H), 7.19–7.15 (m, 3H), 6.28 (dd, J = 17.0, 1.5 Hz, 1H), 6.11–6.02 (m, 2H), 5.95 (bd, J = 8.6 Hz, 1H), 5.88–5.87 (m, 1H), 5.63 (dd, J = 10.2, 1.5 Hz, 1H), 5.17 (q, J = 7.4 Hz, 1H), 2.68–2.57 (m, 2H), 2.26 (s, 3H), 2.20–2.10 (m, 2H). ¹³C NMR (CDCl₃, 75 MHz): δ = 164.7, 152.0, 151.8, 141.5, 130.9, 128.5, 128.5, 126.9, 126.1, 107.6, 106.2, 47.4, 35.8, 32.4, 13.7. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{17}H_{20}NO_2$ 270.2, found 270.5. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{17}H_{19}NO_2K$ 308.1047, found 308.1049. IR (cm^{-1}): 3267 (w), 3062 (w), 3027 (w), 2923 (w), 2861 (w), 1655 (s), 1625 (m), 1535 (s), 1496 (m), 1454 (m), 1407 (m), 1384 (w), 1314 (w), 1278 (w), 1239 (m), 1219 (m), 1066 (w), 1020 (m), 984 (m), 957 (m), 846 (w), 785 (m), 748 (m), 698 (s), 567 (w), 495 (m). R_f (hexane/EtOAc 7:3): 0.3.

2-Chloro-*N*-(1-(5-methylfuran-2-yl)-3-phenylpropyl)acetamide (20b). A 10 mL flask was charged with 2-chloroacetamide (91 mg, 1.0 mmol), 3-phenylpropionaldehyde (69 μ L, 0.5 mmol), and Bi(OTf)₃ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (0.05 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a yellow oil (46 mg, 32%). ¹H NMR (CDCl₃, 300 MHz): δ = 7.31–7.28 (m, 2H), 7.21–7.16 (m, 3H), 6.76 (bd, J = 8.5 Hz, 1H), 6.10 (d, J = 3.1 Hz, 1H), 5.91–5.90 (m, 1H), 5.09 (quart, J = 7.4 Hz, 1H), 4.04 (s, 2H), 2.66–2.60 (m, 2H), 2.28 (s, 3H), 2.23–2.12 (m, 2H). ¹³C NMR (CDCl₃, 75 MHz): δ = 165.1, 152.1, 151.4, 141.2, 128.6, 128.5, 126.2, 107.8, 106.2, 47.7, 42.8, 35.5, 32.4, 13.7. MS (ESI) m/z : $[M + Na]^+$ calcd for $C_{16}H_{18}ClNO_2Na$ 314.1, found 314.3. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{16}H_{18}ClNO_2K$ 330.0658, found 330.0658. IR (cm^{-1}): 3280 (w), 3062 (w), 3027 (w), 2923 (w), 2863 (w), 2076 (w), 1657 (s), 1603 (w), 1527 (m), 1496 (m), 1454 (m), 1410 (w), 1384 (w), 1334 (w), 1219 (m), 1176 (w), 1154 (w), 1055 (m), 1033 (m), 1020 (m), 938 (w), 783 (s), 749 (m), 698 (s), 564 (m), 485 (m). R_f (hexane/EtOAc 4:1): 0.4.

Ethyl 1-(5-Methylfuran-2-yl)-3-phenylpropyl)carbamate (20c). A 10 mL screw-cap vial was charged with urethane (45 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μ L, 0.5 mmol), Bi(OTf)₃ (7 mg, 0.025 mmol, 2 mol %), and DCM (2 mL). The mixture was cooled to 0 °C, and 2-methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) was added. The reaction was stirred at rt for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 12:1 → 9:1 → 4:1) yielded the

product as a yellow oil (68 mg, 47%). $^1\text{H NMR}$ (CDCl_3 , 300 MHz): δ = 7.28–7.24 (m, 2H), 7.18–7.15 (m, 3H), 6.04 (bd, J = 2.8 Hz, 1H), 5.87–5.85 (m, 1H), 5.05–4.81 (m, 1H), 4.81–4.66 (m, 1H), 4.11 (q, J = 7.1 Hz, 2H), 2.67–2.56 (m, 2H), 2.24 (s, 3H), 2.12–2.03 (m, 2H), 1.22 (t, J = 7.1 Hz, 3H). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz): δ = 156.7, 152.7, 151.7, 141.5, 128.5, 126.1, 107.1, 106.1, 61.1, 49.1, 36.2, 32.3, 14.7, 13.7. MS (ESI) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{21}\text{NO}_3\text{Na}$ 310.1, found 310.3. HRMS (MALDI) m/z : $[\text{M} + \text{K}]^+$ calcd for $\text{C}_{17}\text{H}_{21}\text{NO}_3\text{K}$ 326.1153, found 326.1154. IR (cm^{-1}): 3319 (w), 3062 (w), 3027 (w), 2981 (w), 2924 (w), 2863 (w), 1693 (s), 1604 (w), 1514 (m), 1497 (m), 1454 (m), 1376 (w), 1329 (m), 1240 (s), 1219 (s), 1172 (m), 1133 (w), 1047 (s), 1033 (m), 1020 (s), 960 (w), 909 (w), 875 (w), 845 (w), 779 (s), 749 (m), 699 (s), 558 (m), 505 (m). R_f (hexane/EtOAc 4:1): 0.6.

Benzyl (1-(5-Methylfuran-2-yl)-3-phenylpropyl)carbamate (20d). A 10 mL screw-cap vial was charged with benzyl carbamate (76 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μL , 0.5 mmol), $\text{Bi}(\text{OTf})_3$ (7 mg, 0.025 mmol, 2 mol %), and DCM (2 mL). The mixture was cooled to 0 $^\circ\text{C}$, and 2-methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) was added. The reaction was stirred at rt for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 12:1 \rightarrow 9:1 \rightarrow 4:1) yielded the product as a colorless solid (79 mg, 45%). Mp: 67–69 $^\circ\text{C}$. $^1\text{H NMR}$ (CDCl_3 , 300 MHz): δ = 7.37–7.15 (m, 10H), 6.06 (d, J = 3.0 Hz, 1H), 5.89–5.87 (m, 1H), 5.16–5.01 (m, 3H), 4.83–4.78 (m, 1H), 2.67–2.60 (m, 2H), 2.26 (s, 3H), 2.17–2.07 (m, 2H). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz): δ = 155.8, 152.4, 151.8, 141.5, 136.6, 128.7, 128.6, 128.5, 128.3, 126.1, 107.2, 106.1, 67.0, 49.3, 36.1, 32.4, 13.7. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{24}\text{NO}_3$ 350.18, found 350.00. HRMS (MALDI) m/z : $[\text{M} + \text{K}]^+$ calcd for $\text{C}_{22}\text{H}_{23}\text{NO}_3\text{K}$ 388.1310, found 388.1317. IR (cm^{-1}): 3265 (w), 1683 (s), 1585 (w), 1539 (s), 1497 (m), 1454 (m), 1441 (m), 1386 (w), 1358 (w), 1324 (m), 1289 (s), 1257 (s), 1242 (s), 1218 (s), 1197 (m), 1155 (m), 1138 (m), 1090 (m), 1041 (s), 1019 (s), 995 (m), 967 (m), 943 (m), 931 (m), 911 (m), 779 (s), 746 (s), 724 (m), 697 (s), 621 (m), 589 (m), 578 (m), 512 (m), 485 (m), 459 (s). R_f (hexane/EtOAc 4:1): 0.3.

tert-Butyl (1-(5-Methylfuran-2-yl)-3-phenylpropyl)carbamate (20e). A 10 mL flask was charged with *tert*-butyl carbamate (70 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μL , 0.5 mmol), and $\text{Bi}(\text{OTf})_3$ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 1 h via syringe pump to the solution. The reaction mixture was stirred at 25 $^\circ\text{C}$ for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a yellow oil (120 mg, 76%). $^1\text{H NMR}$ (CDCl_3 , 300 MHz): δ = 7.30–7.16 (m, 5H), 6.04 (d, J = 3.0 Hz, 1H), 5.88–5.87 (m, 1H), 4.76 (d, J = 18.4 Hz, 3H), 2.67–2.61 (m, 2H), 2.26 (s, 3H), 2.14–2.03 (m, 2H), 1.45 (s, 9H). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz): δ = 155.3, 153.0, 151.6, 141.7, 128.6, 128.5, 126.0, 106.9, 106.1, 48.8, 36.4, 32.4, 28.5, 28.5, 13.7. MS (ESI) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_3\text{Na}$ 338.2, found 338.4. HRMS (MALDI) m/z : $[\text{M} + \text{K}]^+$ calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_3\text{K}$ 354.1472, found 354.1476. IR (cm^{-1}): 3347 (w), 3028 (w), 2979 (w), 2932 (w), 1697 (s), 1603 (m), 1497 (m), 1454 (m), 1392 (m), 1367 (s), 1248 (s), 1153 (s), 1047 (m), 1024 (s), 856 (m), 749 (s), 699 (s), 546 (m), 493 (m). R_f (hexane/EtOAc 4:1): 0.6.

tert-Butyl ((2S)-3-Methyl-1-((1-(5-methylfuran-2-yl)-3-phenylpropyl)amino)-1-oxobutan-2-yl)carbamate (22). A 10 mL flask was charged with (*S*)-*tert*-butyl (1-amino-3-methyl-1-oxobutan-2-yl)carbamate (130 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μL , 0.5 mmol), and $\text{Bi}(\text{OTf})_3$ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). 2-Methylfuran (0.14 mL, 1.5 mmol, 3.0 equiv) in DCM (2 mL) was added over 2 h via syringe pump to the solution. The reaction mixture was stirred at 25 $^\circ\text{C}$ for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 9:1) yielded the product as a colorless

solid (128 mg, 62%, ratio of diastereomers 2:1). Mp: 85–87 $^\circ\text{C}$. $^1\text{H NMR}$ (CDCl_3 , 300 MHz): δ = 7.30–7.15 (m, 5H), 6.23–6.15 (m, 1H), 6.06–6.04 (m, 1H), 5.87–5.86 (m, 1H), 5.10–5.04 (m, 2H), 3.91–3.81 (m, 1H), 2.65–2.58 (m, 2H), 2.26–2.24 (m, 3H), 2.17–2.08 (m, 2H), 1.43 (s, 9H), 0.99–0.89 (m, 6H). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz) (peaks are not assigned to diastereomers): δ = 170.8, 156.0, 152.0, 151.8, 141.4, 128.6, 128.5, 126.1, 126.1, 107.4, 106.2, 106.1, 80.0, 60.6, 47.3, 47.2, 35.8, 35.6, 32.4, 30.9, 28.4, 19.5, 19.3, 17.9, 13.7, 13.6. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{35}\text{N}_2\text{O}_4$ 415.26, found 415.15. HRMS (MALDI) m/z : $[\text{M} + \text{K}]^+$ calcd for $\text{C}_{24}\text{H}_{34}\text{N}_2\text{O}_4\text{K}$ 453.2150, found 453.2142. IR (cm^{-1}): 3681 (w), 3301 (w), 2966 (m), 2924 (m), 2872 (w), 2845 (w), 2248 (w), 1683 (m), 1649 (s), 1604 (w), 1517 (m), 1497 (m), 1454 (m), 1391 (m), 1366 (m), 1298 (m), 1246 (m), 1167 (s), 1053 (m), 1033 (m), 1018 (m), 878 (w), 850 (w), 784 (m), 731 (s), 698 (s), 647 (m), 566 (w), 517 (m), 493 (m), 462 (m). R_f (hexane/EtOAc 4:1): 0.4.

***N*-(1-(5-Methylthiophene-2-yl)-3-phenylpropyl)benzamide (23a).** A 10 mL screw-cap vial was charged with benzamide (73 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μL , 0.5 mmol), 2-methylthiophene (0.15 mL, 1.5 mmol, 3.0 equiv), $\text{Bi}(\text{OTf})_3$ (16 mg, 0.025 mmol, 5 mol %), and DCM (6 mL). The reaction was stirred at 35 $^\circ\text{C}$ for 16 h. After being cooled to room temperature, the reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (102 mg, 61%). Mp: 152–154 $^\circ\text{C}$. $^1\text{H NMR}$ (CDCl_3 , 300 MHz): δ = 7.70 (d, J = 7.7 Hz, 2H), 7.52–7.39 (m, J = 14.7, 7.3 Hz, 3H), 7.31–7.16 (m, 5H), 6.82 (d, J = 3.3 Hz, 1H), 6.62 (d, J = 3.0 Hz, 1H), 6.23 (bd, J = 8.2 Hz, 1H), 5.46 (q, J = 7.4 Hz, 1H), 2.75 (t, J = 7.9 Hz, 2H), 2.46 (s, 3H), 2.40–2.25 (m, 2H). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz): δ = 166.6, 143.2, 141.5, 139.2, 134.5, 131.7, 128.7, 128.7, 128.6, 127.1, 126.2, 125.1, 124.8, 49.7, 38.3, 32.7, 15.5. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NOS}$ 336.1, found 336.4. HRMS (MALDI) m/z : $[\text{M} + \text{K}]^+$ calcd for $\text{C}_{21}\text{H}_{21}\text{NOSK}$ 374.0975, found 374.0975. IR (cm^{-1}): 3288 (w), 3061 (w), 3027 (w), 2920 (w), 2858 (w), 2244 (w), 1633 (s), 1602 (m), 1579 (m), 1530 (s), 1489 (s), 1453 (m), 1327 (m), 1288 (m), 1229 (m), 1184 (w), 1158 (w), 1075 (m), 1044 (w), 1029 (m), 1001 (w), 908 (m), 869 (w), 844 (w), 798 (m), 730 (s), 694 (s), 647 (m), 616 (m), 531 (m), 492 (m). R_f (hexane/EtOAc 4:1) = 0.5.

***N*-(1-(2,4-Dimethoxyphenyl)-3-phenylpropyl)benzamide (23c).** A 10 mL screw-cap vial was charged with benzamide (73 mg, 0.6 mmol), 3-phenylpropionaldehyde (69 μL , 0.5 mmol), and $\text{Bi}(\text{OTf})_3$ (7 mg, 0.01 mmol, 2 mol %) in DCM (2 mL). The solution was stirred at 25 $^\circ\text{C}$ for 5 min and cooled to 0 $^\circ\text{C}$. Then 1,3-dimethoxybenzene (0.20 mL, 1.5 mmol, 3.0 equiv) was added. The mixture was stirred at 25 $^\circ\text{C}$ for 16 h. The reaction mixture was diluted with EtOAc and filtered over a short plug of Celite and silica gel. The plug was rinsed with additional EtOAc. The combined filtrates were concentrated under reduced pressure. Purification of the crude residue by chromatography (hexane/EtOAc 4:1) yielded the product as a colorless solid (109 mg, 58%). Mp: 125–127 $^\circ\text{C}$. $^1\text{H NMR}$ (CDCl_3 , 300 MHz): δ = 7.73–7.69 (m, 2H), 7.45–7.36 (m, 3H), 7.27–7.13 (m, 7H), 6.49–6.42 (m, 2H), 5.30 (q, J = 7.5 Hz, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 2.72–2.51 (m, 2H), 2.34–2.10 (m, 2H). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz): δ = 166.3, 160.4, 158.4, 142.0, 135.2, 131.3, 130.1, 128.6, 128.5, 128.4, 127.0, 125.9, 122.0, 104.3, 99.6, 55.6, 55.5, 52.6, 37.1, 33.1. MS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{26}\text{NO}_3$ 376.19, found 376.33. HRMS (MALDI) m/z : $[\text{M} + \text{K}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{NO}_3\text{K}$ 414.1466, found 414.1462. IR (cm^{-1}): 3315 (w), 2999 (w), 2835 (w), 1634 (s), 1616 (m), 1591 (m), 1578 (w), 1527 (s), 1505 (s), 1448 (m), 1419 (m), 1361 (m), 1299 (m), 1260 (s), 1209 (s), 1175 (m), 1157 (s), 1126 (s), 1080 (m), 1037 (s), 922 (m), 871 (w), 819 (s), 803 (m), 786 (m), 725 (s), 692 (s), 680 (s), 633 (m), 546 (m), 508 (m), 475 (m). R_f (hexane/EtOAc 4:1): 0.2. Analytical data are consistent with literature.⁴³

***N*-(Mesityl(phenyl)methyl)benzamide (25).** Compound 25 was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.38 mL, 2.7 mmol, 2.7 equiv), and $\text{Bi}(\text{OTf})_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 $^\circ\text{C}$ for 24 h. Purification by chromatography (hexane/EtOAc 12:1

→ 9:1) yielded the product as a colorless solid (235 mg, 71%). Mp: 75–77 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.84–7.81 (m, 2H), 7.53–7.40 (m, 3H), 7.29–7.19 (m, 3H), 7.17–7.14 (m, 2H), 7.00 (bd, *J* = 8.6 Hz, 1H), 6.89–6.85 (m, 3H), 2.31 (s, 6H), 2.28 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.8, 141.2, 137.4, 136.9, 134.8, 134.5, 131.8, 130.3, 128.8, 128.7, 127.1, 126.9, 126.1, 52.2, 21.1, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₃H₂₄NO 330.19, found 330.32. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₃H₂₃NOK 368.1411, found 368.1410. IR (cm⁻¹): 2918 (w), 1640 (m), 1600 (w), 1579 (w), 1513 (s), 1482 (s), 1376 (w), 1344 (w), 1272 (m), 1192 (w), 1127 (w), 1028 (w), 906 (w), 860 (w), 803 (w), 789 (w), 727 (s), 707 (s), 697 (m), 687 (m), 663 (w), 650 (w), 620 (w), 592 (m), 533 (m). *R_f* (hexane/EtOAc 4:1): 0.5. Analytical data are consistent with literature.¹²

N-((2,4-Dimethylphenyl)(phenyl)methyl)benzamide (26). Compound 26 was synthesized according to TP 2 benzamide (145 mg, 1.2 mmol), benzaldehyde (99 μL, 1.2 mmol), *m*-xylene (0.37 mL, 3.0 mmol, 3.0 equiv), Bi(OTf)₃ (33 mg, 0.05 mmol, 5 mol %), and TfOH (4 μL, 0.05 mmol, 5 mol %) in DCE (4 mL) at 150 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (239 mg, 76%). Mp: 154–156 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.83–7.80 (m, *J* = 6.9, 1.6 Hz, 2H), 7.54–7.41 (m, 3H), 7.33–7.25 (m, 5H), 7.06–6.86 (m, 3H), 6.64–6.46 (m, 2H), 2.33 (s, 3H), 2.31 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.4, 141.3, 137.4, 136.7, 136.5, 134.4, 131.9, 131.8, 128.8, 128.8, 127.6, 127.5, 127.2, 127.0, 127.0, 54.4, 21.1, 19.6. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₂H₂₂NO 316.17, found 316.32. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₂H₂₁NOK 354.1255, found 354.1251. IR (cm⁻¹): 3344 (w), 2919 (w), 1628 (s), 1576 (m), 1524 (s), 1498 (m), 1486 (s), 1379 (w), 1360 (m), 1303 (m), 1278 (m), 1237 (m), 1211 (w), 1135 (w), 1075 (m), 1053 (w), 1030 (m), 978 (w), 930 (w), 853 (w), 819 (s), 805 (m), 738 (s), 713 (s), 702 (s), 689 (s), 663 (m), 646 (m), 620 (m), 586 (s), 563 (m), 542 (m). *R_f* (hexane/EtOAc 4:1): 0.5.

N-((3-Chlorophenyl)(mesityl)methyl)benzamide (28a). Compound 28a was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), 3-chlorobenzaldehyde (0.14 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (196 mg, 54%). Mp: 130–132 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.85–7.82 (m, 2H), 7.54–7.44 (m, 3H), 7.26–7.16 (m, 3H), 7.08–7.02 (m, 1H), 6.97 (bd, *J* = 8.5 Hz, 1H), 6.91 (s, 2H), 6.82 (bd, *J* = 8.6 Hz, 1H), 2.31 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ = 167.0, 143.8, 137.8, 136.8, 134.8, 134.3, 134.2, 132.0, 130.5, 130.0, 128.9, 127.2, 127.1, 126.2, 124.3, 51.8, 21.1, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₃H₂₃ClNO 364.15, found 364.28. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₃H₂₂ClNOK 402.1022, found 402.1024. IR (cm⁻¹): 1640 (s), 1600 (w), 1580 (m), 1570 (m), 1512 (s), 1481 (s), 1443 (m), 1423 (m), 1379 (w), 1336 (m), 1272 (m), 1236 (w), 1207 (w), 1190 (m), 1146 (w), 1128 (w), 1099 (w), 1073 (w), 1055 (m), 1033 (m), 1001 (w), 893 (w), 861 (m), 795 (w), 762 (s), 746 (m), 713 (s), 703 (m), 685 (s), 665 (w), 650 (m), 595 (s), 551 (m), 523 (m), 486 (w). *R_f* (hexane/EtOAc 4:1): 0.6.

N-((3-Bromophenyl)(mesityl)methyl)benzamide (28b). Compound 28b was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), 3-bromobenzaldehyde (0.14 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (222 mg, 54%). Mp: 139–141 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.88–7.78 (m, 2H), 7.57–7.40 (m, 3H), 7.42–7.33 (m, 1H), 7.32–7.30 (m, 1H), 7.16 (t, *J* = 7.8 Hz, 1H), 7.12–7.05 (m, 1H), 6.99–6.96 (m, 1H), 6.91 (s, 2H), 6.79 (bd, *J* = 8.6 Hz, 1H), 2.30 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ = 167.0, 144.1, 137.8, 136.8, 134.3, 134.2, 132.0, 130.5, 130.3, 130.2, 129.1, 128.9, 127.2, 124.9, 123.1, 51.8, 21.1, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₃H₂₃BrNO 408.10, found 408.68. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₃H₂₂BrNOK 446.0516, found 446.0504. IR (cm⁻¹): 2967 (w), 1640 (s), 1580 (m), 1512 (s), 1481 (s), 1272 (m), 1055 (m), 1033 (s), 861 (m), 760 (s), 709 (s), 687 (s), 675 (m), 595 (s), 548 (m). *R_f* (hexane/EtOAc 4:1): 0.5.

N-((4-Chlorophenyl)(mesityl)methyl)benzamide (28c). Compound 28c was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), 4-chlorobenzaldehyde (172 mg, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (261 mg, 72%). Mp: 62–64 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.83–7.81 (m, 2H), 7.56–7.43 (m, 3H), 7.28–7.26 (m, 1H), 7.25–7.24 (m, 1H), 7.11–7.07 (m, 2H), 6.96–6.90 (m, 3H), 6.79 (bd, *J* = 8.3 Hz, 1H), 2.29 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.9, 140.0, 137.8, 136.8, 134.4, 132.8, 132.0, 130.5, 128.9, 128.8, 127.6, 127.1, 51.8, 21.1, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₃H₂₃ClNO 364.15, found 364.28. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₃H₂₂ClNOK 402.1022, found 402.1017. IR (cm⁻¹): 3313 (w), 2921 (w), 1638 (m), 1579 (w), 1508 (m), 1483 (s), 1378 (w), 1343 (w), 1311 (m), 1178 (w), 1150 (w), 1091 (m), 1058 (m), 1033 (m), 1013 (m), 909 (w), 850 (m), 824 (m), 799 (m), 768 (m), 709 (s), 691 (s), 658 (m), 601 (m), 577 (m), 562 (m), 532 (m), 499 (m). *R_f* (hexane/EtOAc 4:1): 0.6.

N-((4-Fluorophenyl)(mesityl)methyl)benzamide (28d). Compound 28d was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), 4-fluorobenzaldehyde (0.13 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (243 mg, 64%). Mp: 60–62 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.84–7.81 (m, 2H), 7.53–7.43 (m, 3H), 7.14–7.09 (m, 2H), 7.00–6.95 (m, 3H), 6.90 (s, 2H), 6.81 (bd, *J* = 8.5 Hz, 1H), 2.30 (s, 6H), 2.29 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.9, 163.6, 160.3, 137.6, 137.0 (d, *J* = 3.1 Hz), 136.8, 134.6, 134.3, 131.9, 130.5, 128.9, 127.8 (d, *J* = 8.0 Hz), 127.1, 115.7, 115.4, 51.7, 21.1, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₃H₂₃FNO 348.18, found 348.32. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₃H₂₂FNOK 386.1317, found 386.1316. IR (cm⁻¹): 3301 (w), 2921 (w), 1639 (m), 1601 (w), 1580 (w), 1505 (s), 1481 (m), 1378 (w), 1310 (w), 1222 (m), 1157 (m), 1098 (w), 1057 (w), 1033 (m), 1014 (m), 849 (m), 833 (m), 804 (w), 770 (m), 710 (m), 691 (m), 661 (m), 612 (m), 585 (m), 533 (m), 503 (m), 459 (m). *R_f* (hexane/EtOAc 4:1): 0.6.

N-((2-Chloro-5-nitrophenyl)(mesityl)methyl)benzamide (28e). Compound 28e was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), 2-chloro-5-nitrobenzaldehyde (190 mg, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (269 mg, 66%). Mp: 220–222 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 8.34 (dd, *J* = 2.6, 0.7 Hz, 1H), 8.11–8.07 (m, 1H), 7.85–7.82 (m, 2H), 7.58–7.44 (m, 4H), 6.87 (bs, 2H), 6.80 (d, *J* = 6.6 Hz, 1H), 6.51 (bd, *J* = 6.6 Hz, 1H), 2.28 (s, 3H), 2.21 (s, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ = 167.1, 146.7, 141.6, 140.2, 138.5, 137.1, 133.5, 132.3, 131.9, 131.4, 131.0, 129.0, 127.3, 124.1, 123.4, 52.8, 21.6, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₃H₂₂ClN₂O₃ 409.13, found 409.30. HRMS (MALDI) *m/z*: [M + K]⁺ calcd for C₂₃H₂₁ClN₂O₃K 447.0872, found 447.0871. IR (cm⁻¹): 2921 (w), 1640 (s), 1595 (w), 1580 (w), 1513 (s), 1481 (s), 1423 (w), 1379 (w), 1342 (m), 1318 (w), 1273 (m), 1238 (w), 1207 (w), 1190 (w), 1147 (w), 1129 (w), 1099 (w), 1073 (w), 1055 (w), 1033 (m), 1001 (w), 909 (w), 889 (w), 861 (m), 795 (w), 762 (m), 742 (m), 713 (s), 685 (s), 650 (w), 595 (m), 552 (m), 523 (m), 486 (w), 458 (w). *R_f* (hexane/EtOAc 4:1): 0.5.

N-((Mesityl)naphthalen-2-yl)methyl)benzamide (28f). Compound 28f was synthesized according to TP 2 from benzamide (121 mg, 1.0 mmol), 1-naphthaldehyde (0.16 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a yellow oil (110 mg, 29%). ¹H NMR (CDCl₃, 300 MHz): δ = 8.07–8.04 (m, 1H), 7.92–7.88 (m, 1H), 7.83–7.75 (m, 3H), 7.51–7.33 (m, 7H), 7.26–7.23 (m, 1H), 6.92 (s, 2H), 6.75 (bd, *J* = 7.8 Hz, 1H), 2.36 (s, 6H), 2.30 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.0, 137.1, 136.9, 134.8, 134.4, 134.1, 133.8, 131.7, 130.6, 129.0, 129.0, 128.8, 127.1, 126.9, 126.2, 126.0, 125.3, 123.9, 51.9, 21.8, 21.0. MS (ESI) *m/z*: [M + H]⁺ calcd for C₂₇H₂₆NO 380.20, found 380.36. HRMS (MALDI) *m/z*: [M + K]⁺

calcd for $C_{27}H_{25}NOK$ 418.1568, found 418.1556. IR (cm^{-1}): 3300 (w), 2921 (w), 2243 (w), 1638 (s), 1600 (w), 1579 (w), 1508 (s), 1481 (s), 1397 (w), 1373 (w), 1348 (w), 1298 (w), 1262 (w), 1238 (w), 1150 (w), 1074 (w), 1033 (m), 907 (m), 852 (m), 800 (m), 778 (s), 728 (s), 709 (s), 691 (s), 647 (m), 624 (w), 602 (m), 563 (m), 534 (m), 506 (m). R_f (hexane/EtOAc 4:1): 0.5.

***N*-(Mesityl(phenyl)methyl)-4-methoxybenzamide (29a)**. Compound 29a was synthesized according to TP 2 from 4-methoxybenzamide (154 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (140 mg, 39%). Mp: 184–186 °C. 1H NMR ($CDCl_3$, 300 MHz): δ = 8.88 (bd, J = 8.6 Hz, 1H), 8.30 (dd, J = 7.8, 1.8 Hz, 1H), 7.49–7.43 (m, 1H), 7.31–7.28z (m, 1H), 7.24–7.17 (m, 3H), 7.13–7.05 (m, 2H), 6.99 (d, J = 8.3 Hz, 1H), 6.89 (s, 2H), 3.94 (s, 3H), 2.33 (s, 6H), 2.28 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ = 164.8, 157.7, 142.0, 137.1, 136.9, 135.6, 133.0, 132.9, 130.2, 128.6, 126.6, 126.0, 121.6, 121.5, 111.4, 56.1, 51.7, 21.0, 20.8. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{24}H_{26}NO_2$ 360.20, found 360.36. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{24}H_{25}NO_2K$ 398.1517, found 398.1512. IR (cm^{-1}): 2967 (w), 1632 (m), 1598 (m), 1518 (m), 1345 (m), 1292 (m), 1260 (m), 1186 (m), 1062 (s), 1033 (s), 1016 (s), 867 (m), 850 (m), 807 (m), 781 (w), 698 (s), 623 (m), 584 (m). R_f (hexane/EtOAc 4:1): 0.4.

4-Bromo-*N*-(mesityl(phenyl)methyl)benzamide (29b). Compound 29b was synthesized according to TP 2 from 4-bromobenzamide (206 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (228 mg, 56%). Mp: 163–165 °C. 1H NMR ($CDCl_3$, 300 MHz): δ = 7.72–7.69 (m, 2H), 7.61–7.57 (m, 2H), 7.33–7.24 (m, 3H), 7.16 (d, J = 1.3 Hz, 2H), 6.97 (d, J = 8.5 Hz, 1H), 6.91 (s, 2H), 6.80 (bd, J = 8.4 Hz, 1H), 2.30 (s, 6H), 2.30 (s, 9H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ = 165.9, 141.0, 137.5, 136.9, 134.6, 133.3, 132.1, 130.4, 128.8, 128.7, 127.1, 126.5, 126.1, 52.3, 21.1, 21.0. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{23}H_{23}BrNO$ 408.10, found 408.22. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{23}H_{22}BrNOK$ 446.0516, found 446.0507. IR (cm^{-1}): 2922 (w), 1636 (m), 1589 (m), 1568 (w), 1516 (s), 1493 (w), 1477 (s), 1448 (m), 1378 (w), 1343 (m), 1309 (m), 1269 (m), 1146 (w), 1127 (w), 1111 (w), 1074 (w), 1051 (w), 1028 (w), 1011 (m), 891 (w), 856 (w), 843 (m), 792 (w), 754 (s), 733 (s), 698 (s), 650 (w), 594 (m), 535 (m), 524 (m), 497 (w). R_f (hexane/EtOAc 9:1): 0.7.

***N*-(Mesityl(phenyl)methyl)-4-nitrobenzamide (29c)**. Compound 29c was synthesized according to TP 2 from 4-nitrobenzamide (169 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a yellow solid (251 mg, 67%). Mp: 161–163 °C. 1H NMR ($CDCl_3$, 300 MHz): δ = 8.31 (d, J = 8.9 Hz, 2H), 7.99 (d, J = 8.9 Hz, 2H), 7.35–7.29 (m, 3H), 7.16–7.14 (m, 2H), 6.99 (d, J = 8.5 Hz, 1H), 6.96–6.84 (m, 3H), 2.31 (s, 6H), 2.30 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ = 164.9, 149.9, 140.5, 140.1, 137.8, 136.9, 134.2, 130.5, 128.9, 128.3, 127.3, 126.1, 124.1, 52.7, 21.1, 21.0. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{23}H_{23}N_2O_3$ 375.17, found 375.32. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{23}H_{22}N_2O_3K$ 413.1262, found 413.1263. IR (cm^{-1}): 1665 (m), 1639 (m), 1614 (w), 1600 (m), 1516 (s), 1493 (m), 1479 (s), 1448 (m), 1380 (w), 1341 (m), 1325 (w), 1304 (m), 1273 (w), 1206 (w), 1156 (w), 1112 (w), 1095 (w), 1048 (w), 1028 (w), 910 (w), 871 (w), 852 (m), 821 (w), 788 (w), 781 (w), 754 (m), 734 (s), 719 (m), 698 (s), 648 (w), 620 (w), 597 (m), 548 (m), 533 (m), 506 (m). R_f (hexane/EtOAc 4:1): 0.6.

2-Fluoro-*N*-(mesityl(phenyl)methyl)benzamide (29d). Compound 29d was synthesized according to TP 2 from 2-fluorobenzamide (142 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless oil (254 mg, 73%). 1H NMR ($CDCl_3$, 300 MHz): δ = 8.19–8.13 (m, 1H), 7.66–7.59 (m, 1H), 7.47–7.39 (m, 1H), 7.29–7.02 (m, 8H), 6.87 (s, 2H),

2.29 (s, 6H), 2.25 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ = 162.8 (d, J = 3.4 Hz), 162.6, 159.3, 141.1, 137.3, 136.9, 134.9, 133.5 (d, J = 9.5 Hz), 132.5 (d, J = 2.1 Hz), 130.3, 128.7, 126.9, 125.9, 125.0 (d, J = 3.2 Hz), 120.9 (d, J = 11.0 Hz), 116.1 (d, J = 25.1 Hz), 52.0, 21.0, 20.8. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{23}H_{23}FNO$ 348.18, found 348.32. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{23}H_{22}FNOK$ 386.1317, found 386.1318. IR (cm^{-1}): 3028 (w), 2967 (w), 2919 (w), 1664 (s), 1614 (m), 1582 (w), 1512 (s), 1494 (s), 1478 (s), 1448 (m), 1378 (w), 1346 (w), 1302 (m), 1285 (m), 1205 (m), 1155 (w), 1135 (w), 1095 (m), 1058 (w), 1030 (m), 958 (w), 908 (w), 846 (m), 821 (m), 779 (m), 754 (s), 726 (s), 697 (s), 641 (m), 598 (s), 577 (w), 547 (m), 532 (m), 504 (s). R_f (hexane/EtOAc 4:1): 0.7.

2-Chloro-*N*-(mesityl(phenyl)methyl)acetamide (29f). Compound 29f was synthesized according to TP 2 from 2-chloroacetamide (94 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 100 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a yellow oil (270 mg, 89%). 1H NMR ($CDCl_3$, 300 MHz): δ = 7.45 (bd, J = 9.1 Hz, 1H), 7.29–7.18 (m, 3H), 7.09–7.06 (m, 2H), 6.86 (s, 2H), 6.77 (d, J = 9.1 Hz, 1H), 4.16 (d, J = 15.2 Hz, 1H), 4.03 (d, J = 15.2 Hz, 1H), 2.25 (s, 3H), 2.23 (s, 6H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ = 165.3, 140.3, 137.4, 136.8, 134.2, 130.2, 128.7, 127.1, 125.8, 51.8, 42.9, 20.9, 20.8. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{18}H_{21}ClNO$ 302.13, found 302.24. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{18}H_{20}ClNOK$ 340.0865, found 340.0865. IR (cm^{-1}): 3301 (w), 3028 (w), 2958 (w), 2920 (w), 2865 (w), 1654 (s), 1611 (m), 1584 (w), 1517 (s), 1494 (s), 1448 (m), 1409 (m), 1378 (m), 1319 (w), 1259 (m), 1192 (w), 1148 (w), 1085 (w), 1062 (w), 1030 (m), 984 (w), 910 (w), 848 (m), 807 (w), 771 (m), 732 (s), 697 (s), 647 (m), 634 (m), 619 (m), 581 (m), 565 (m), 532 (m), 496 (m), 465 (m). R_f (hexane/EtOAc 4:1): 0.4.

Ethyl (Mesityl(phenyl)methyl)carbamate (29g). Compound 29g was synthesized according to TP 2 from urethane (92 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), mesitylene (0.42 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a yellow oil (98 mg, 33%). 1H NMR ($CDCl_3$, 300 MHz): δ = 7.31–7.22 (m, 3H), 7.16–7.13 (m, 2H), 6.88 (s, 2H), 6.52 (bd, J = 9.1 Hz, 1H), 5.40 (bd, J = 8.5 Hz, 1H), 4.21–4.11 (m, 2H), 2.29 (s, 3H), 2.22 (s, 6H), 1.27 (t, J = 7.1 Hz, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ = 156.7, 141.7, 137.3, 136.8, 135.4, 130.2, 128.6, 126.8, 125.9, 61.2, 53.4, 21.0, 20.9, 14.8. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{19}H_{24}NO_2$ 298.18, found 298.05. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{19}H_{23}NO_2K$ 336.1360, found 336.1355. IR (cm^{-1}): 3347 (w), 2977 (w), 2919 (w), 1703 (s), 1611 (w), 1583 (w), 1494 (s), 1448 (m), 1377 (m), 1330 (m), 1297 (m), 1245 (m), 1220 (s), 1172 (m), 1117 (m), 1077 (m), 1046 (s), 1023 (s), 963 (w), 935 (w), 913 (w), 887 (w), 848 (m), 796 (w), 775 (m), 733 (s), 697 (s), 633 (m), 601 (m), 542 (m), 528 (m), 496 (m), 458 (m). R_f (hexane/EtOAc 4:1): 0.4.

***N*-(4-Methoxyphenyl)(phenyl)methylbenzamide (30a)**. Compound 30a was synthesized according to TP 2 benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), anisole (0.30 mL, 3.0 mmol, 3.0 equiv), and $Bi(OTf)_3$ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 100 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 → 9:1) yielded the product as a colorless solid (80 mg, 25%, ratio of regioisomers 4:1). Mp: 172–174 °C. 1H NMR ($CDCl_3$, 300 MHz) (peaks are listed only for major regioisomer): δ = 7.84–7.80 (m, 2H), 7.51–7.44 (m, 3H), 7.38–7.29 (m, 5H), 7.23–7.20 (m, 2H), 6.90–6.85 (m, 2H), 6.65–6.60 (m, 1H), 6.41 (d, J = 7.7 Hz, 1H), 3.80 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz) (peaks are not assigned to regioisomers): δ = 166.6, 159.2, 141.8, 134.4, 133.8, 131.8, 131.6, 129.8, 129.2, 128.9, 128.9, 128.8, 128.7, 128.4, 127.6, 127.5, 127.2, 127.1, 126.8, 121.3, 114.3, 111.8, 57.1, 55.8, 55.5, 55.0. MS (ESI) m/z : $[M + H]^+$ calcd for $C_{21}H_{20}NO_2$ 318.15, found 318.28. HRMS (MALDI) m/z : $[M + K]^+$ calcd for $C_{21}H_{19}NO_2K$ 356.1047, found 356.1047. IR (cm^{-1}): 3305 (w), 3061 (w), 2955 (w), 1629 (s), 1600 (w), 1578 (m), 1535 (m), 1509 (m), 1490 (m), 1461 (w), 1360 (w), 1314 (m), 1246 (m), 1203 (w), 1175 (m), 1112 (w), 1081 (w), 1031 (m), 1001 (w), 934 (w), 908 (w), 865 (w), 827 (m), 799 (w), 782 (w), 746 (w), 698 (s), 662 (m), 618

(w), 573 (m), 509 (w). R_f (hexane/EtOAc 4:1): 0.5. Analytical data are consistent with literature.¹²

***N*-(3-Bromo-4-methoxyphenyl)(phenyl)methylbenzamide (30b)**. Compound **30b** was synthesized according to TP 2 benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), 2-bromoanisole (0.38 mL, 3.0 mmol, 3.0 equiv), Bi(OTf)₃ (33 mg, 0.05 mmol, 5 mol %), and TfOH (4 μ L, 0.05 mmol, 5 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 \rightarrow 9:1) yielded the product as a colorless solid (114 mg, 35%). Mp: 146–148 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.83–7.80 (m, 2H), 7.52–7.42 (m, 4H), 7.37–7.20 (m, 6H), 6.86 (d, J = 8.5 Hz, 1H), 6.63 (bd, J = 7.7 Hz, 1H), 6.37 (d, J = 7.7 Hz, 1H), 3.88 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.6, 155.4, 141.2, 135.3, 134.2, 132.4, 131.9, 129.0, 128.8, 128.0, 127.9, 127.6, 127.2, 112.2, 112.1, 56.7, 56.5. MS (ESI) m/z : [M + H]⁺ calcd for C₂₁H₁₉BrNO₂ 396.06, found 397.91. HRMS (MALDI) m/z : [M + K]⁺ calcd for C₂₁H₁₈BrNO₂K 434.0153, found 434.0146. IR (cm⁻¹): 3279 (w), 2981 (w), 1633 (s), 1601 (w), 1578 (m), 1525 (m), 1489 (s), 1457 (m), 1438 (w), 1401 (w), 1356 (w), 1315 (m), 1303 (m), 1278 (m), 1257 (s), 1204 (w), 1184 (m), 1157 (w), 1083 (w), 1053 (m), 1022 (m), 1001 (w), 936 (w), 884 (w), 847 (w), 812 (m), 804 (m), 784 (w), 740 (m), 702 (s), 681 (m), 663 (m), 641 (m), 617 (m), 582 (s). R_f (hexane/EtOAc 4:1): 0.2.

***N*-(3-Chloro-4-methoxyphenyl)(phenyl)methylbenzamide (30c)**. Compound **30c** was synthesized according to TP 2 benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), 2-chloroanisole (0.38 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 \rightarrow 9:1) yielded the product as a colorless solid (142 mg, 40%). Mp: 144–146 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.83–7.80 (m, 2H), 7.52–7.15 (m, 9H), 7.19–7.15 (m, 1H), 6.89 (d, J = 8.5 Hz, 1H), 6.63 (bd, J = 7.5 Hz, 1H), 6.37 (d, J = 7.7 Hz, 1H), 3.89 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.6, 154.5, 141.2, 134.9, 134.2, 131.9, 129.3, 129.0, 128.8, 128.0, 127.6, 127.2, 127.1, 122.9, 112.3, 56.8, 56.4. MS (ESI) m/z : [M + H]⁺ calcd for C₂₁H₁₉ClNO₂ 352.11, found 352.24. HRMS (MALDI) m/z : [M + K]⁺ calcd for C₂₁H₁₈ClNO₂K 390.0658, found 390.0651. IR (cm⁻¹): 3297 (w), 3060 (w), 1631 (s), 1601 (w), 1578 (w), 1528 (m), 1500 (s), 1491 (s), 1458 (w), 1404 (w), 1356 (w), 1305 (m), 1279 (m), 1257 (s), 1205 (w), 1186 (w), 1159 (w), 1085 (w), 1063 (m), 1023 (m), 1002 (w), 948 (w), 937 (w), 891 (w), 878 (w), 813 (m), 803 (w), 784 (w), 739 (w), 703 (s), 693 (s), 619 (w), 610 (w), 586 (s), 547 (w). R_f (hexane/EtOAc 4:1): 0.2.

***N*-(2-Methoxy-4,6-dimethylphenyl)(phenyl)methylbenzamide (30d)**. Compound **30d** was synthesized according to TP 2 benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), 3,5-dimethylanisole (408 mg, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 130 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 \rightarrow 9:1) yielded the product as a yellow oil (255 mg, 74%). ¹H NMR (CDCl₃, 300 MHz): δ = 8.01 (bd, J = 9.5 Hz, 1H), 7.84–7.81 (m, 2H), 7.50–7.41 (m, 3H), 7.28–7.17 (m, 5H), 6.91 (d, J = 9.5 Hz, 1H), 6.73 (s, 1H), 6.64 (s, 1H), 3.70 (s, 3H), 2.50 (s, 3H), 2.33 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.5, 158.1, 142.1, 138.5, 137.8, 135.0, 131.5, 128.7, 128.3, 127.2, 126.7, 126.4, 125.0, 124.6, 111.1, 55.9, 50.7, 21.6, 20.4. MS (ESI) m/z : [M + H]⁺ calcd for C₂₃H₂₄NO₂ 346.18, found 346.32. HRMS (MALDI) m/z : [M + K]⁺ calcd for C₂₃H₂₃NO₂K 384.1360, found 384.1356. IR (cm⁻¹): 1657 (s), 1611 (m), 1602 (m), 1580 (m), 1508 (s), 1481 (s), 1464 (s), 1447 (m), 1380 (w), 1346 (m), 1304 (s), 1265 (m), 1234 (m), 1183 (m), 1154 (m), 1134 (m), 1093 (s), 1050 (m), 1029 (m), 1001 (m), 971 (w), 937 (w), 914 (w), 891 (w), 833 (m), 800 (m), 733 (s), 710 (s), 695 (s), 668 (m), 639 (m), 606 (s), 592 (s), 568 (s), 518 (m). R_f (hexane/EtOAc 4:1): 0.4.

***N*-(5-Bromothiophene-2-yl)(phenyl)methylbenzamide (30f)**. Compound **30f** was synthesized according to TP 2 benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), 2-bromothiophene (0.29 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 80 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 \rightarrow 9:1) yielded the product as a colorless solid (133 mg, 36%). Mp: 159–161 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.82–7.79 (m, 2H), 7.53–7.34 (m, 7H), 6.90 (d, J = 3.8 Hz, 1H), 6.72 (bd, J = 7.7 Hz, 1H), 6.63 (dd, J = 3.8, 1.0 Hz, 1H), 6.55 (d, J = 7.9 Hz,

1H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.5, 147.4, 140.3, 134.0, 132.1, 129.9, 129.1, 128.9, 128.5, 127.3, 127.2, 126.5, 112.2, 53.7. MS (ESI) m/z : [M + H]⁺ calcd for C₁₈H₁₅BrNOS 372.01, found 372.44. HRMS (MALDI) m/z : [M + Na]⁺ calcd for C₁₈H₁₄BrNOSNa 393.9872, found 393.9887. IR (cm⁻¹): 3282 (w), 3030 (w), 1640 (s), 1602 (w), 1578 (w), 1521 (m), 1488 (m), 1455 (w), 1439 (m), 1359 (m), 1311 (m), 1271 (w), 1248 (w), 1214 (m), 1195 (w), 1155 (w), 1084 (w), 1050 (w), 1029 (w), 966 (m), 925 (w), 902 (w), 820 (w), 801 (m), 784 (m), 721 (m), 700 (s), 691 (s), 666 (m), 645 (m), 615 (m), 568 (m), 551 (w), 500 (w), 478 (m). R_f (hexane/EtOAc 4:1): 0.4.

***N*-(Benzofuran-2-yl)(phenyl)methylbenzamide (30g)**. Compound **30g** was synthesized according to TP 2 benzamide (121 mg, 1.0 mmol), benzaldehyde (0.12 mL, 1.2 mmol), benzofuran (0.32 mL, 3.0 mmol, 3.0 equiv), and Bi(OTf)₃ (66 mg, 0.1 mmol, 10 mol %) in DCE (4 mL) at 50 °C for 24 h. Purification by chromatography (hexane/EtOAc 12:1 \rightarrow 9:1) yielded the product as a colorless solid (30 mg, 9%). Mp: 137–139 °C. ¹H NMR (CDCl₃, 300 MHz): δ = 7.86–7.83 (m, 2H), 7.53–7.30 (m, 12H), 7.28–7.19 (m, 1H), 6.92 (bd, J = 8.1 Hz, 1H), 6.67–6.64 (m, 2H). ¹³C NMR (CDCl₃, 75 MHz): δ = 166.7, 156.1, 155.3, 139.0, 134.1, 132.0, 129.0, 128.8, 128.3, 128.2, 127.4, 127.3, 124.5, 123.1, 121.3, 111.5, 105.0, 52.1. MS (ESI) m/z : [M + H]⁺ calcd for C₂₂H₁₈NO₂ 328.13, found 328.26. HRMS (MALDI) m/z : [M + K]⁺ calcd for C₂₂H₁₇NO₂K 366.0891, found 366.0888. IR (cm⁻¹): 3318 (w), 1630 (s), 1600 (m), 1577 (w), 1537 (s), 1490 (m), 1454 (m), 1329 (m), 1284 (w), 1270 (m), 1254 (s), 1203 (w), 1168 (m), 1142 (m), 1104 (w), 1081 (m), 1029 (w), 1002 (w), 966 (m), 904 (m), 857 (w), 823 (m), 802 (m), 752 (s), 742 (s), 725 (s), 711 (s), 697 (s), 690 (s), 647 (s), 624 (m), 615 (m), 585 (m), 565 (m), 461 (m). R_f (hexane/EtOAc 4:1): 0.3.

■ ASSOCIATED CONTENT

Supporting Information

¹H NMR and ¹³C NMR spectra of all products. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b00662.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: g.manolikakes@chemie.uni-frankfurt.de.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was financially supported by the Fonds der Chemischen Industrie (Liebig Fellowship to G.M. and A.E.S.). We thank Prof. Michael Göbel (Goethe University Frankfurt) for his support and Rockwood Lithium (Frankfurt) and Evonik Industries (Darmstadt) for the generous gift of chemicals.

■ REFERENCES

- (a) Gall, E. L.; Haurena, C.; Sengmany, S.; Martens, T.; Troupel, M. *J. Org. Chem.* **2009**, *74*, 7970. (b) Selvam, N. P.; Perumal, P. T. *Tetrahedron Lett.* **2006**, *47*, 7481. (c) Kogen, H.; Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T. *Org. Lett.* **2002**, *4*, 3359. (d) Rosen, T. J.; Coffman, K. J.; McLean, S.; Crawford, R. T.; Bryce, D. K.; Gohda, Y.; Tsuchiya, M.; Nagahisa, A.; Nakane, M.; Lowe, J. A., III. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 281.
- (2) Pin, F.; Comesse, S.; Daich, A. *Tetrahedron* **2011**, *67*, 5564.
- (3) Belyk, K. M.; Morrison, H. G.; Jones, P.; Summa, V. WO 2006060730, 2007.
- (4) (a) Yazici, A.; Pyne, S. G. *Synthesis* **2009**, 339. (b) Petrini, M.; Torregiani, E. *Synthesis* **2007**, 159. (c) Maryanoff, B. E.; Zhang, H. C.; Cohen, J. H.; Turchi, I. J.; Maryanoff, C. A. *Chem. Rev.* **2004**, *104*, 1431. (d) Speckamp, W. N.; Moolenaar, M. J. *Tetrahedron* **2000**, *56*, 3817.
- (5) (a) Li, M.; Luo, B.; Liu, Q.; Hu, Y.; Ganesan, A.; Huang, P.; Wen, S. *Org. Lett.* **2014**, *16*, 10. (b) Salama, T. A. *Synlett* **2013**, 713. (c) Jaratjaroonphong, J.; Krajangri, S.; Reutrakul, V. *Tetrahedron Lett.*

- 2012, 53, 2476. (d) Nandi, G. C.; Samai, S.; Kumar, R.; Singh, M. S. *Tetrahedron Lett.* **2009**, 50, 7220. (e) Shirakawa, S.; Kobayashi, S. *Org. Lett.* **2006**, 8, 4939. (f) Ben-Ishai, D.; Altman, J.; Bernstein, Z.; Peled, N. *Tetrahedron* **1977**, 34, 467.
- (6) Trost, B. M. *Science* **1991**, 254, 1471.
- (7) (a) Anastas, P.; Eghbali, N. *Chem. Soc. Rev.* **2010**, 39, 301. (b) Horváth, I. T.; Anastas, P. T. *Chem. Rev.* **2007**, 107, 2169.
- (8) Typical procedures use at least 1 equiv of the acid (often > 3 equiv). In some cases, the acid is used as solvent (see refs 4 and 5)
- (9) (a) Shirakawa, S.; Kobayashi, S. *Org. Lett.* **2006**, 8, 4939. (b) Liu, J.; He, T.; Wang, L. *Tetrahedron* **2011**, 67, 3420.
- (10) For recent three-component aza-Friedel-Crafts reactions of 2-naphthol, aldehydes, and amides or urea, see: (a) Nandi, G. C.; Samai, S.; Kumar, R.; Singh, M. S. *Tetrahedron Lett.* **2009**, 50, 7220. (b) Kumar, A.; Kumar, M.; Gupta, M. K. *Tetrahedron Lett.* **2009**, 50, 7024. (c) Lei, M.; Ma, L.; Hu, L. *Tetrahedron Lett.* **2009**, 50, 6393. (d) Hajipour, A. R.; Ghayeb, Y.; Sheikhan, N.; Ruoho, A. E. *Tetrahedron Lett.* **2009**, 50, 5649.
- (11) For recent three-component aza-Friedel-Crafts reactions of 2-naphthol, aldehydes, and carbamates, see: (a) Shaterian, H. R.; Hosseinian, A.; Ghashang, M. *Synth. Commun.* **2009**, 39, 2560. (b) Shaterian, H. R.; Hosseinian, A.; Ghashang, M. *Tetrahedron Lett.* **2008**, 49, 5804.
- (12) For similar reactions with arylboron reagents as nucleophiles, see: (a) Beisel, T.; Manolikakes, G. *Org. Lett.* **2013**, 15, 6046. (b) Morin, M. S. T.; Lu, Y.; Black, D. A.; Arndtsen, B. A. *J. Org. Chem.* **2012**, 77, 2013.
- (13) Schneider, A. E.; Manolikakes, G. *Synlett* **2013**, 2057.
- (14) Schneider, A. E.; Beisel, T.; Shemet, A.; Manolikakes, G. *Org. Biomol. Chem.* **2014**, 12, 2356.
- (15) Halli, J.; Manolikakes, G. *Eur. J. Org. Chem.* **2013**, 7471.
- (16) During the preparation of this manuscript Jaratjaroonphong et al. reported a similar Bi(OTf)₃-catalyzed three-component reaction, which is limited to electron-rich (hetero)arenes: Jaratjaroonphong, J.; Tuengpanya, S.; Ruengsangtongkul, S. *J. Org. Chem.* **2015**, 80, 559.
- (17) Mayr, H.; Bug, T.; Gotta, M. F.; Hering, N.; Irrgang, B.; Janker, B.; Kempf, B.; Loos, R.; Ofial, A. R.; Remennikov, G.; Schimmel, H. *J. Am. Chem. Soc.* **2001**, 123, 9500.
- (18) Reviews: (a) Ollevier, T. *Org. Biomol. Chem.* **2013**, 11, 2740. (b) Bothwell, J. M.; Krabbe, S. W.; Mohan, R. S. *Chem. Soc. Rev.* **2011**, 40, 4649. (c) Gaspard-Illoughmane, H.; Le Roux, C. *Eur. J. Org. Chem.* **2004**, 2517.
- (19) For some recent applications, see: (a) Zhang, L.; Li, Z.; Fan, R. *Org. Lett.* **2013**, 15, 2482. (b) Li, Z.; Plancq, B.; Ollevier, T. *Chem.—Eur. J.* **2012**, 18, 3144. (c) Rubenbauer, P.; Herdtweck, E.; Strassner, T.; Bach, T. *Angew. Chem., Int. Ed.* **2008**, 47, 10106. (d) Rueping, M.; Nachtsheim, B. J.; Kuenkel, A. *Org. Lett.* **2007**, 9, 825. (e) Qin, H.; Yamagiwa, N.; Matsunaga, S.; Shibasaki, M. *Angew. Chem., Int. Ed.* **2007**, 46, 409. (f) Rueping, M.; Nachtsheim, B. J.; Scheidt, T. *Org. Lett.* **2006**, 8, 3717.
- (20) For Bi(OTf)₃-catalyzed Mannich-type amidoalkylation and Mannich-type reactions with reactive nucleophiles, see: (a) Pin, F.; Comesse, S.; Garrigues, B.; Marchalin, S.; Daïch, A. *J. Org. Chem.* **2007**, 72, 1181. (b) Ollevier, T.; Nadeau, E. *Org. Biomol. Chem.* **2007**, 5, 3126. (c) Ollevier, T.; Nadeau, E. *J. Org. Chem.* **2004**, 69, 9292. (d) Ollevier, T.; Ba, T. *Tetrahedron Lett.* **2003**, 44, 9003.
- (21) For the use of dbpy as mechanistic probe to determine between Lewis and Brønsted acid catalysis, see: Wabnitz, T. C.; Yu, J.-Q.; Spencer, J. B. *Chem.—Eur. J.* **2004**, 10, 484.
- (22) Dang, T. T.; Boeck, F.; Hintermann, L. *J. Org. Chem.* **2011**, 76, 9353.
- (23) (a) Kaczanowska, K.; Wiesmuller, K.-H.; Schaffner, A.-P. *ACS Med. Chem. Lett.* **2010**, 1, 530. (b) Campoli-Richards, D.; Lackner, T.; Monk, J. *Drug* **1987**, 34, 411. (c) Musher, D. M.; Fainstein, V.; Young, E. *J. Antimicrob. Agents Chemother.* **1980**, 254.
- (24) No racemization of the stereocenter was observed.
- (25) Clayden, J.; Greeves, N.; Warren, S.; Wothers, P. In *Organic Chemistry*; Oxford University Press: Oxford, 2001.
- (26) The reactive acylimine species might be too short-lived to be detected by common NMR or IR methods
- (27) Gilbert, E. E. *Synthesis* **1972**, 30.
- (28) The transition between *N*-acylimines and *N*-acyliminium ions is fluent; therefore, in most cases it cannot be determined what species is present.
- (29) An activation of the nucleophile via an arene–Bi complex is also possible; see: Müller-Becker, S.; Frank, W.; Schneider, J. *Z. Anorg. Allg. Chem.* **1993**, 619, 1073.
- (30) Depending on the arene, between 0 and 30% of the bis(hetero)arylmethane derivatives could be isolated. In the case of very reactive heteroarenes, such as indole or pyrrole, only the bisheteroarylmethane derivatives were obtained.
- (31) For the bismuth-catalyzed alkylation of heteroarenes with benzyl alcohols, see: Rueping, M.; Nachtsheim, B. J. *Beilstein J. Org. Chem.* **2010**, 6 (6), 1.
- (32) (a) Maryanoff, B. E.; McComsey, D. F.; Duhl-Emswiler, B. A. *J. Org. Chem.* **1983**, 48, 5062. (b) Schoemaker, H. E.; Boer-Terpstra, T.; Dukink, J.; Speckamp, W. N. *Tetrahedron* **1980**, 36, 143. (c) Wijnberg, J. B. P. A.; de Boer, J. J. J.; Speckamp, W. N. *Recl. Trav. Chim., Pays-Bas* **1978**, 97, 227.
- (33) For an example of an acid-catalyzed enamide formation, see also: Reeves, J. T.; Tan, Z.; Reeves, D. C.; Song, J. J.; Han, Z. S.; Xu, Y.; Tang, W.; Yang, B.-S.; Razavi, H.; Harcken, C.; Kuzmich, D.; Mahaney, P. E.; Lee, H.; Busacca, C. A.; Senanayake, C. H. *Org. Process Res. Dev.* **2014**, 18 (7), 904.
- (34) (a) Hoang, C. T.; Bouillère, F.; Johannesen, S.; Zulauf, A.; Panel, C.; Pouilhès, A.; Gori, D.; Alezra, V.; Kouklovsky, C. *J. Org. Chem.* **2009**, 74, 4177. (b) Carocci, A.; Catalano, A.; Corbo, F.; Duranti, A.; Amoroso, R.; Franchini, C.; Lentini, G.; Tortorella, V. *Tetrahedron: Asymmetry* **2000**, 11, 3619.
- (35) Wu, W.; Yuan, X.; Hu, J.; Wu, X.; Wei, Y.; Liu, Z.; Lu, J.; Ye, J. *Org. Lett.* **2013**, 15 (17), 4524.
- (36) Li, Y.; Chen, H.-H.; Wang, C.-F.; Xu, X.-L.; Feng, Y.-S. *Tetrahedron Lett.* **2012**, 53, 5796.
- (37) Holzwarth, R.; Bartsch, R.; Cherkaoui, Z.; Solladij, G. *Chem.—Eur. J.* **2004**, 10, 3931.
- (38) Brasche, G.; Garcia-Fortanet, J.; Buchwald, S. L. *Org. Lett.* **2008**, 10, 2207.
- (39) Yao, C.-H.; Song, J.-S.; Chen, C.-T.; Yeh, T.-K.; Hsieh, T.-C.; Wu, S.-H.; Huang, C.-Y.; Huang, Y.-L.; Wang, M.-H.; Liu, Y. W.; Tsai, C.-H.; Kumar, C. R.; Lee, J.-C. *Eur. J. Med. Chem.* **2012**, 55, 32.
- (40) Noland, W. E.; Lanzatella, N. P. *J. Heterocyclic Chem.* **2009**, 46, 1285.
- (41) Einhorn, A.; Bischoff, E.; Ladisch, C.; Mauermayer, T.; Schupp, G.; Spröngerts, E.; Szelinski, B. *Justus Liebigs Ann. Chem.* **1905**, 343, 207.
- (42) Tischler, A. N.; Tischler, M. H. *Tetrahedron Lett.* **1997**, 37, 3407.
- (43) Sorimachi, K.; Terada, M. *J. Am. Chem. Soc.* **2008**, 130, 14452.